

Coming of Age

The Centre for Youth Substance Abuse Research

Report for 2018 and the first ten years of CYSAR

2008—
2018



THE UNIVERSITY
OF QUEENSLAND
AUSTRALIA

04	Director's greeting	56	2018 Research Publications
06	Our mission and aims	71	2018 Staff Listing
10	CYSAR 2018 Achievements	74	Our Students
21	Selected highlights from 10 years	77	Major Partners and Collaborators
30	Spotlight on NHMRC Fellowship holders	82	Scientific Advisory Board
52	2018 Research Grants and Contracts	84	Centre Contact Details

\$11,100,000

in direct research income
generated from grants and tenders

\$4,000,000

matching funds from
UQ and QUT

\$5,550,000

in direct research income
from competitive grants

85

Meeting papers with abstracts
published in scientific journals

Generated

3X

the funding

provided by the UQef
donation from other sources

615

Peer reviewed journal
articles, reviews, editorials
commentaries letters

\$1,800,000

UQ internal funding secured
to support research

6

**CYSAR students
awarded PhDs**

\$36,000,000

in collaborative
research funding

Greetings from the Director

The Centre for Youth Substance Abuse Research (CYSAR) in the Faculty of Health and Behavioural Sciences (HABS) at The University of Queensland (UQ) is the only Australian research centre focusing exclusively on young people and substance use.

Since its establishment in 2008 as a UQ Faculty Centre, CYSAR has gained recognition as a national centre of research excellence by the award of the Commonwealth Department of Health's Drug and Alcohol Program (DAP) funding Grant (2018-2019; Connor and Hides). This funding has allowed the Centre to substantially extend its research impact across areas of harm reduction, substance supply reduction, youth epidemiology, and alcohol and drug policy. These areas reflect key research priorities of the Federal Government's National Drug Strategy 2017-2026.

In 2018 CYSAR welcomed new Board member Mr Mitchell Giles and returning Board Member Professor Leanne Hides.



129

high quality peer reviewed
publications



19

national and international
invited talks

Mr Giles is CEO of Lives Lived Well (LLW), the major non-government provider of addiction prevention and treatment services across Queensland which co-funds and collaborates with the UQ LLW Chair of Alcohol Drugs and Mental Health, Professor Leanne Hides. Professor Hides was formerly the QUT based Deputy Director of CYSAR (2010-16). After an extensive international search, Leanne was appointed UQ LLW Professor in 2017 to undertake research on the treatment of comorbidity between addictive and other mental disorders.



45

published abstracts, oral presentations and posters



26

papers



12

international meetings



10

high performing PhD students

Mitchell and Leanne’s expertise is invaluable to the Board, particularly the translational aspects of their work.

Over the past 12 months, a strong alliance has formed between the LLW Group and CYSAR, including formal affiliations with CYSAR for the LLW Chair and research fellows. 2018 marked the conclusion of the formal cross-university funding partnership with QUT. The Centre’s strong collaborative relationships with QUT will remain with senior QUT staff supporting CYSAR through their continued Advisory Board membership.

I am proud of the achievements of our staff in the 2018 calendar year. With our clinical partners, we are driving translatable research outcomes that are tangibly reducing the impact of substance use on young people, and their families. In 2018 alone, there have been 129 high quality peer reviewed publications from salaried staff and 19 national and international invited talks. CYSAR’s research outcomes were also presented in 45 published abstracts, oral presentations and posters including 26 papers at 12 international meetings.

CYSAR currently has 10 high performing PhD students, the majority holding externally competitive scholarships. Two of our students, Dr Jason Coates and Dr Kiri Patton completed joint Master of Clinical Psychology and Doctor of Philosophy programs in 2018. This 2018 annual report and ten year review details the research achievements of our staff and the impact they have made on youth substance use policy, prevention and treatment.



Professor Jason Connor
Director (UQ)

CYSAR is one of the four Commonwealth-funded alcohol and other drug research centres in Australia and the only centre dedicated to youth-focused research.



Reduce the prevalence and severity of problem alcohol and drug use in Australian communities



Enhance research capacity informing national efforts to address substance use



Increase knowledge on treatment approaches for emerging drugs of concern and innovative treatment models

Our mission and aims

CYSAR is one of the four Commonwealth-funded alcohol and other drug research centres in Australia and the only centre dedicated to youth-focused research. The Centre is led by Professor Jason Connor (UQ). Professor David Kavanagh (QUT) completed his tenure as QUT Deputy Director in December 2018. CYSAR was established in 2008 through the vision of the Graeme Wood Foundation in partnership with QUT. Mr Wood wanted to make an impact on the complex challenges posed by youth substance use in Australia. CYSAR seeks to reduce the prevalence and severity of problem alcohol and drug use in Australian communities; enhance research capacity informing national efforts to address substance misuse; and increase our knowledge on treatment approaches for emerging drugs of concern and innovative treatment models.

CYSAR aims to:

- Understand the pathways by which young people engage in substance use
- Be at the cutting edge of research into new and innovative ways of preventing and treating problem substance use among young people
- Make significant and tangible improvements to youth service provision
- Positively influence state and national approaches to youth problem substance use prevention and treatment through information dissemination, policy refinement and public advocacy, and
- Ensure youth have a voice and input into the research directions of the Centre



Finding solutions, improving futures, partnering with young people.

Our mission is to promote the health and wellbeing of young people by increasing Australia's capacity to respond effectively to any harm arising from substance use.

CYSAR has a strong track record of delivering high quality research, with translatable outcomes aimed at reducing the impact of substance use on young people, their families and the wider community resulting in significant national health and social economic benefits. Strategic guidance and support is provided by an Advisory Board that has a diverse wealth of experience in health, clinical and youth research, advocacy, media and provision of government and non-government youth alcohol and drug services.

CYSAR researchers are regularly invited to deliver national and international keynote presentations, as well as disseminate their work into clinical services through the delivery of training workshops and clinical resources such as treatment manuals. Several hold adjunct clinical appointments in alcohol and drug services, facilitating research translation.

CYSAR has extensive collaborations and links with other national and international researchers in the alcohol and other drug field and well-established industry and clinical partners across the drug and alcohol, mental health, emergency, housing and social support sectors.



\$13.5M

direct research funding



\$36M

collaborative research
funding

Executive officers of many of these services are represented on the CYSAR Advisory Board and have formal UQ affiliate joint appointments with the Centre.

Since 2008, CYSAR has leveraged more than \$13.5 million in direct research funds (plus an additional \$36 million in collaborative research funding), exceeding more than three times the funding provided by our initial philanthropic donation. CYSAR now operates 100% from external funding.

CYSAR 2018

Achievements



Dr Matthew Gullo

Key Centre Funding and Research Outcomes

CYSAR salaried staff were Chief Investigators on five successful grants and tenders in Canadian dollars, British pounds, Euros, and US dollars in 2018, collectively worth (Australian) \$1.75M. Other successful CYSAR applications submitted in 2018 (commencing in 2019) included a 2 year Medical Research Future Fund (MRFF) Translating Research into Practice Fellowship (\$181,000) to Dr Matthew Gullo. Dr Gullo and Professor Connor were awarded 2 year Innovation Grants through the Metro South Health Research Support Scheme (Queensland Health) amounting to \$94,500.

Professor Wayne Hall is a CI on a 4 year NHMRC Project grant titled “Common mental and substance use disorders in a 28-year follow-up of a community cohort: identification of preventive strategies from adolescence to early midlife” worth \$1.14M led by Professor George Patton and colleagues at the University of Melbourne.

Key Centre Funding and Research Outcomes (continued)

CYSAR research staff authored or co-authored 129 peer reviewed publications published, accepted, or submitted in 2018 (and accepted 2019) from salaried staff members. CYSAR researchers gave 19 national and international invited talks; CYSAR research outcomes were presented in 45 published abstracts, oral presentations and posters from CYSAR staff and RHD students including 26 at 12 international meetings.

Four PhDs were awarded to CYSAR students at UQ and QUT in 2018-2019. The majority of the ten continuing PhD students hold Australian Government Research Training Program Scholarships. In 2018, 16 student-led papers were published, accepted, or submitted for publication (and subsequently published) in *Addiction*, *Addictive Behaviors*, *Drug and Alcohol Dependence*, *Drug and Alcohol Review*, *Frontiers in Psychiatry*, *International Journal of Public Health*, *Journal of Applied Research in Intellectual Disabilities*, *Journal of Consulting and Clinical Psychology*, *Personality and Individual Differences*, *PLoS ONE*, and *Substance Use and Misuse*.



National Consultation Invitations

- Professor Hall was reappointed to the Federal Government's Australian Advisory Committee on Medical Uses of Cannabis for 2 years by Federal Health Minister Hunt.
- Minister Hunt personally invited Professor Jason Connor on behalf of CYSAR to provide him with a briefing and advice on the National Alcohol Strategy.
- The Health Minister also requested an update on clinical evidence and advice on e-cigarettes.
- Professor Connor was invited to the National Male Health Forum to consult on the development of a national strategy.
- Professor Connor was invited to consult on a national strategy for the National Child Health Action Plan.
- Professor Connor was invited to attend the National Injury Prevention Roundtable. Alcohol is one of the most likely risk factors for injury across most age groups but the sector has been underrepresented in this forum.
- CYSAR and LLW together made a submission to the Draft National Alcohol Strategy 2018-2026, in addition to the direct Ministerial request for feedback.
- Dr Matt Gullo attended a workshop with representatives of peak bodies, research centres, and clinical services to draft recommendations for Alcohol and Drug Treatment Reform, hosted by St Vincent's Health, NSW.
- Professor Wayne Hall was invited to Chair the International Advisory Board for the Australian Centre for Cannabinoid Clinical and Research Excellence, an NHMRC Centre of Research Excellence.



Dr Gary Chan, UN Office on Drugs and Crime

International Consultation Invitations

- Dr Gary Chan was seconded to the UN Office on Drugs and Crime in Vienna for 4 months. He co-authored two reports for the Annual Review Questionnaire, the primary instrument used annually to assess drug use and related issues in UN member states. These reports provided recommendations for future improvement of drug measurement.
- Professor Wayne Hall was commissioned by the International Narcotics Control Board (INCB), a quasi-judicial UN drug treaty monitoring agency, to contribute a Thematic Chapter for the Board's Annual Report on medical cannabis. Thematic Chapters of the INCB are reserved for major contemporary policy topics.
- Professor Jason Connor and Dr Matthew Gullo were part of an international consortium of 40 addiction experts who developed a consensus position on the key neuropsychological processes in addiction. It was published in *Addiction*, the top journal in the field.

Awards and Honours

- Professor Hall was profiled in Addiction Lives. This series in leading journal Addiction records the views and personal experiences of people who have made major international contributions to the evolution of ideas in addiction science.
- Dr Gary Chan received the Early Career Researcher Travel award to attend leading North American scientific meeting College on Problems of Drug Dependence, San Diego California (only 4 Australian ECRS were awarded in 2018).
- Professor Wayne Hall's Annual Lecture for the Society for the Study of Addiction in York, UK, "The future of the international drug control system and national drug prohibitions" published in Addiction (#1 ranked alcohol and other drugs journal) was shortlisted for the EMCDDA Scientific Award 2018 in the category 'Drug policy and supply reduction interventions research'.

Upcoming Research Publications

- Professor Hall was appointed to a new Lancet series on drug use and will be leading the series' cannabis paper. Co-authors will include CYSAR Adjunct Fellow Dr Janni Leung and CYSAR postdoc Dr Daniel Stjepanović.
- Professor Hall has been reappointed by the World Health Organization to prepare a report on the public health implications of medical cannabis programs.

Research Students

- CYSAR is pleased to welcome two new f/t PhD students, Ms Angela Wanigasooriya and Ms Chui Ying Vivian Chiu.
- Two CYSAR RHD students at UQ were awarded their PhDs, Dr Jason Coates and Dr Kiri Patton, both supervised by Professor Connor and Dr Gullo.



Vivian Chui, 2018 RHD student



(L to R) Dr Kiri Patton, Professor Connor and Dr Jason Coates at the 2019 CYSAR graduation

Media

There was a strong media response to Professors Connor & Hall's Lancet commentary on minimum safe levels of alcohol use, which was timely and highly relevant given the dated Australian drinking guidelines and forthcoming National Alcohol Strategy. This was also a key document in advising the Director of the US National Institutes of Health (NIH) on a matter central to scientific and public trust, eventually resulting in the termination of the \$20M NIH funded Moderate Alcohol and Cardiovascular Health trial.

Continued coverage

The official Australian alcohol guidelines of "no more than two drinks daily" is unsafe and must be replaced by "less than 10 drinks per week". *Channel 9, Courier-Mail, Daily Telegraph, Herald Sun, Adelaide Now, Business Insider, nine.com.au, Banten News, Cardiology Today, GK Men, My Science, MSN, and WXXV25.*

One extra glass of wine will shorten your life by 30 minutes: UQ's Wayne Hall anticipates recommending lower drinking limits will come up against opposition. *The Guardian, Yahoo!*



The official Australian alcohol guidelines of "no more than two drinks daily" is unsafe and must be replaced by "less than 10 drinks per week".

BUSINESS
INSIDER
AUSTRALIA

The
Courier Mail

The Daily Telegraph

Herald Sun

The Advertiser



nine
.com.au

BantenNews.co.id
- sajian berita cepat -



The
Guardian



WXXV 25

yahoo!

Cardiology today



Media (continued)

- In July, Professor Wayne Hall was interviewed on ABC Radio Brisbane regarding findings published in The Lancet Public Health (Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study).
- While in the UK in October, Professor Hall was interviewed by BBC World News on Canada's recent legalisation of cannabis and was invited to blog for the London School of Economics and Political Science.
- In December, Professor Hall's commissioned report for the European Monitoring Centre on Drugs and Drug Addiction on medicinal uses of cannabis was released ahead of schedule, possibly due to the decision by Luxembourg to legalise the recreational use of cannabis, the first European Union country to do so. The report informed the deliberations of the EU Parliament and was cited in a Resolution.

CYSAR Seminars

Following the relocation to the UQ St Lucia campus, the Centre raised its profile by co-hosting three international speakers at public seminars with UQ School of Psychology:

- Professor Reinout Wiers (University of Amsterdam) presented his seminar on Cognitive Bias Training for Substance Use Disorder. Professor Wiers is an internationally renowned addiction treatment expert.
- Dr Susanne Uusitalo (University of Turku, Finland) gave a talk on Self-Control and Vulnerability in Problem Gambling.
- Dr Scott Hadland (Boston University School of Medicine) presented his clinical and research work focusing on adolescents and young adults who use substances, with a particular focus on opioid use disorder.




Matt Gullo (left) and Dr Scott Hadland, Boston University School of Medicine (right)

**Selected
highlights
from 10 years**



2008

The Centre for Youth Substance Abuse Research was established through the vision of the Graeme Wood Foundation. In its inaugural year, the Centre for Youth Substance Abuse Research brought together a world class multidisciplinary team, including the CYSAR Advisory Board, CYSAR Partners, and CYSAR staff and students (pictured above).



Professor John Saunders

2010

Professor John Saunders published a seminal textbook that became a central reference for health professionals working with young people and alcohol. Professor Saunders has worked with the World Health Organization for many years and was responsible for developing the most widely used alcohol screening instrument, the Alcohol Use Disorders Identification Test (AUDIT). He is the Founding and Emeritus Editor-in-Chief of leading addiction journal Drug and Alcohol Review, a Vice-President of the International Society of Addiction Medicine, and a member of WHO's Expert Advisory Panel on Substance Abuse. He was Co-Chair of the Diagnostic and Statistical Manual of Mental Disorders (5th edition) Substance Use Disorders Workgroup from 2003 to 2007.

2011

In May the Australian Drug Foundation convened the International Conference on Drugs and Young People in Melbourne. The conference theme was “Making the Connections” which was chosen as it highlighted the complexity and interaction of factors that influence and impact on young people’s lives; the opportunity for diverse sectors to meet and exchange knowledge and expertise; translating research into practice; and the growing importance of social media and technology in young people’s lives today and its potential role in the future. With over 400 delegates representing young people, practitioners and researchers, CYSAR was privileged to showcase its diverse range of research and consultative activities within its CYSAR Symposium.



The CYSAR team - Caroline, Angela, Jason, John, Leanne, Rosa and Lake-Hui

2012

CYSAR Advisory Board- Long serving members



Professor Bruce Abernethy became the Chair of CYSAR's Advisory Board, serving until 2016. Today he is Executive Dean of our Faculty, of Health and Behavioural Sciences at UQ. CYSAR has been fortunate in its long serving board members, many of whom were there at the creation, including Professor Doune Macdonald, Ms Carrie Fowlie, Professor David Kavanagh, and Professor Ross Young. Also in this year, CYSAR's first PhD student Karen Li was awarded the Trans-Pacific Fellowship to spend three months at a leading research centre in Seattle, and CYSAR's evaluation demonstrating the effectiveness of the North Queensland "Choices" dramatic program to reduce the risk of problem drinking and other risky behaviours during school leaver's celebrations led to new funding allowing this program to continue.

2013

A strong showing at the leading national scientific addiction meeting, the Australasian Professional Society on Alcohol and other Drugs (APSAD) conference demonstrated the early success of the Centre. CYSAR staff presented current research including impulsivity in adolescent drinking; ethical issues of population-level analysis of illicit drug use; using music to increase wellbeing and prevent or treat problem substance use; demonstrating the role of mobile phone applications to promote health and wellbeing; and describing polydrug use amongst cannabis users. CYSAR leadership was shown by Matt Gullo, recipient of the 2013 APSAD Early Career Research Excellence award.



Matthew Gullo (left), receiving the APSAD Early Career Research Excellence award

2014

The 5-year external review required to maintain status as a Faculty-level Centre was conducted at the end of 2014. The review panel was chaired by Professor Steve Allsop, Director of the National Drug Research Institute at Curtin University, and Professor Jane Pirkis, Director of the Centre for Mental Health Evaluation from the School of Population Health at The University of Melbourne. The review commended the Centre for its excellent research performance as indicated by high quality academic outputs, success in funded fellowships and high quality of staff recruited to the Centre. It noted the strong academic relationships within the Centre, and between the UQ and QUT nodes of the Centre, the positive strategies to enhance communication, the strong mentorship provided for research students and early career fellows, and the quality of students and post-doctoral staff who have been attracted to work at the Centre. Challenges associated with the post-philanthropic funding environment and a geographically dispersed centre were highlighted by the review committee.

2015

Professor Wayne Hall (CYSAR Director 2014-2017) was invited by the World Health Organization to write a commissioned review on the adverse effects of cannabis on young people and to present this to an expert meeting held in Stockholm. The report covered what his evidence has shown about recreational cannabis use, including dependence, reduced academic attainment, and increased likelihood of experiencing psychosis.

Professor Hall gave a summary of this report at a UN meeting convened by the UN Office of Drugs and Crime and WHO in Vienna.



Kiri Patton 3MT



Jason Connor (left) and John Saunderson (right)

2016

Long-serving board member Professor David Kavanagh became the Deputy Director in a year of achievement and recognition for CYSAR, including an award for the “Ray’s night out” app, a win for PhD student Kiri Patton in UQ Psychology’s Three Minute Thesis competition, and the second edition of the Addiction Medicine Clinical Guide led by Professor John Saunders. Another highlight for the centre was the Blurred Minds Project Virtual House Party. Dr Timo Dietrich, Professor Jason Connor, and Dr Matthew Gullo, led by Professor Sharyn Rundle-Thiele from Griffith University, ran a highly successful alcohol prevention randomised controlled trial with over 2500 secondary school students, with an average age 14. Positive outcomes were achieved for drinking and change across key outcomes. The trial was funded by an ARC Linkage grant with Catholic Education. Components of the intervention are now included in 183 secondary schools in QLD. The project developed a world’s first virtual reality house party which allows students to experience an immersive ‘chose your own adventure’ simulation.

2017

The academic career of former CYSAR Director and current professorial fellow, Professor Wayne Hall was celebrated on October 2017 at a Festschrift hosted by CYSAR and the National Drug and Alcohol Research Centre. The event was an opportunity to pay tribute to Professor Hall's career of mentorship, research leadership in the field of ethical and evidence-based drug policy, and his role in shaping both national and international drug policy. The event was attended by past and current colleagues and students, as well as leaders in the addictions field. Invited overseas speakers included Professor Sir John Strang (National Addiction Centre and Institute of Psychiatry, Kings College London), Professor Beau Kilmer (RAND Drug Policy Research Centre) and Paul Griffiths (European Monitoring Centre on Drugs and Drug Addiction, Lisbon). Former colleagues and students who also spoke included: Professors Richard Mattick and Louisa Degenhardt (NDARC), Professor Lisa Maher (Kirby Institute) and Professor Jason Connor (CYSAR).



Spotlight on NHMRC Fellowship holders

Four of CYSAR's current six research staff have been awarded NHMRC (National Health and Medical Research Council) Fellowships, which reflects a substantial investment in research excellence aimed at improving the substance-related health of all Australians.



Professor Jason Connor

Professor Jason Connor held a NHMRC of Australia Career Development Fellowship (CDF, Level II) from 2013-2017. After tobacco, problem alcohol use is the second highest preventable cause of death and hospitalisation in Australia. Alcohol Use Disorder (AUD) treatment outcomes remain modest; about one in four patients remain abstinent after psychological treatment and only one in 11 patients will respond effectively to the 'anti-craving' drugs listed on the Australian Pharmaceutical Benefits Scheme (PBS). Consequently, the majority of patients relapse after treatment.

Identification of unique individual differences in AUD patients is likely to provide more effective psychological and pharmacological interventions. In other areas of medicine, tailored patient interventions have improved treatment outcomes considerably. Professor Connor's NHMRC CDF behaviourally and pharmacologically targeted patients' unique psychological and genetic make-up in the context of a randomised control trial (RCT, N=397). A concurrent NHMRC CFD project prospectively examined if machine learning approaches were more effective than expert clinical judgement in predicting AUD treatment outcomes (N=1236).



After tobacco, problem alcohol use is the second highest preventable cause of death and hospitalisation in Australia.

The main findings were:

- Patients with higher alcohol craving profiles who received targeted psychological craving interventions achieved better treatment outcomes than the treatment as usual group, which was generic Cognitive Behavioural Therapy.
- Patients that have a specific genetic profile in the opioid receptor mu 1 polymorphism had greater reductions in alcohol craving when prescribed the 'anti-craving' drug naltrexone.
- Machine learning approaches outperformed expert clinical decision making in predicting treatment outcomes for alcohol dependence.

The outcomes of Professor Connor's NHMRC CDF (II) research are readily applicable to alcohol and drug and mental health treatment services.

Selected NHMRC CDF publications:

- Coates JM, Gullo MJ, Feeney GFX, Young R McD, **Connor JP**. (2018). A randomised trial of personalised cognitive-behaviour therapy for Alcohol Use Disorder in a public health clinic. *Frontiers in Psychiatry* 10, 297.
- Symons M, Gallagher MR, Feeney GFX, Young R McD, **Connor JP**. (2020) Predicting alcohol dependence treatment outcomes: a prospective comparative study of clinical psychologists vs 'trained' machine learning models. *Addiction* 115:2164-2175.
- Symons M, Gallagher MR, Feeney GFX, Young R McD, **Connor JP**. (2019). Machine learning vs addiction therapists: a pilot study predicting alcohol dependence treatment outcome from patient data in behavior therapy with adjunctive medication. *Journal of Substance Abuse Treatment* 99, 156-162.
- **Connor JP**, Coates JM, Gullo MJ, Young RMcD, Law B, Clark P, Voisey J, Feeney GFX. (2020). Alcohol craving is significantly reduced in patients prescribed naltrexone who also carry the oprm1 asn40asp polymorphism (RS1799978), Research Society on Alcoholism Conference (accepted).



... a consistent theme throughout his career has been to improve our understanding of the adverse health effects of cannabis...



Professor Wayne Hall

Professor Hall was awarded the highest NHMRC award, an Australia Fellowship. From 2009-2014 Professor Hall and his team forged a new, innovative research area in the field of addiction neuroethics. From 2014 to 2017 Professor Hall was the Director of CYSAR, and from 2017 has held a part-time role as a Professorial Research Fellow. His international professorial appointments have included the National Addiction Centre, Kings College London, and the London School of Hygiene and Tropical Medicine.

Professor Hall is also one of UQ's and Australia's most recognised health researchers. He has been identified by the Institute for Scientific Information (ISI) as a 'highly cited researcher', representing the top 0.5 % of researchers worldwide. He has published in the highest impact journals, including 30 papers in The Lancet that included the editorial lead on a number of invited special issues and commissioned papers. In 2007, Professor Hall was honoured with a personal profile in The Lancet. In recognition of his contribution "for service to community health" Professor Hall has been awarded an Order of Australia. He is also an elected Fellow of the Academy of the Social Sciences Australia.

Professor Hall's research profile is broad, but a consistent theme throughout his career has been to improve our understanding of the adverse health effects of cannabis, how best to respond to opioid dependence, and the epidemiology of illicit drug use and mental disorders. His work has a strong, translational public policy focus and he has been at the forefront of advocacy for evidence-based policies to reduce the harms caused by alcohol, cannabis, the opioids and other drugs. He is highly sought after internationally as an expert on government policy. He is an invited member of the WHO Expert Committee on Drug Dependence, and an expert advisor to the World Bank and the United Nations Office on Drugs and Crime. In 2011-2014 Professor Hall was a WHO-nominated Member of the International Narcotics Control Board, an independent, quasi-judicial body that monitors compliance by nation states with United Nations international drug control treaties. He has highly productive international research collaborations at these institutes and regularly consults for European Union drugs agency the European Monitoring Centre on Drugs and Drug Addiction. In 2017 he was invited to join the Australian Advisory Council on the Medical Uses of Cannabis convened by the Federal Department of Health. He is the invited Chair of the International Advisory Board of the Australian Centre for Cannabinoid Clinical and Research Excellence, a NHMRC Centre of Excellence.

Selected publications:

- Connor, J.P., Haber, P., **Hall, W.** Seminar: Alcohol use disorders. *Lancet* 2016; 387: 988-98
- **Hall, W.** What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? *Addiction* 2015; 110: 19-35.
- **Hall, W.** U.S. policy responses to calls for the medical use of cannabis. *Yale Journal of Biology and Medicine* 2015; 88: 257-64.
- **Hall, W.**, Lynskey, M. Why it is probably too soon to assess the public health effects of legalisation of recreational cannabis use in the USA. *Lancet Psychiatry* 2016; 3: 900-6.
- **Hall, W.**, Renström, M., Poznyak, V., editors. The health and social effects of nonmedical cannabis use. Geneva: World Health Organization; 2016.
- **Hall, W.** Patton, G., Stockings, E., Weier, M., Lynskey, M., Morley, K. I., et al. Why young people's substance use matters for global health. *Lancet Psychiatry* 2016; 3: 265-79.
- **Hall, W.** The future of the international drug control system and national drug prohibitions. Society for Study of Addiction Annual Lecture, York, November 2016



Associate Professor Matthew Gullo

Associate Professor Matthew Gullo held a NHMRC Early Career Fellowship (Tier II, Clinical) from 2012-2016. Currently, he holds a Medical Research Future Fund (MRFF) of Australia Translating Research into Practice (TRIP) Fellowship. Alcohol use is a leading cause of adolescent morbidity and mortality. Prevention approaches for adolescent alcohol use have, at best, modest effect sizes and progress has been slow over the past two decades. A key obstacle is the poor understanding of the causal mechanisms through which known risk factors, like impulsivity, lead to alcohol use. Another difficulty is determining whether new treatment approaches are impacting on these mechanisms, because of inherent limitations in clinical trial methodology. Addressing these issues became the focus of Associate Professor Gullo's NHMRC Fellowship.

Associate Professor Gullo developed a world-first human preclinical model of adolescent impulsivity and alcohol use, the Experimental Paradigm for Investigating Impulsive Consumption (EPIIC). EPIIC can elucidate causal mechanisms by inducing impulsive states that increase drinking in the laboratory and records the preceding changes in cognition, affect, and inhibitory control. EPIIC revealed that only reward-seeking impulses, not those arising from negative affect or disinhibition, were causally related to drinking in young people. Furthermore, these reward-seeking impulses had the same impact on alcohol consumption, irrespective of peer influence, which increased alcohol use in an additive fashion.

The body of work provided further support for Associate Professor Gullo's bioSocial Cognitive Theory (bSCT) of substance use, which has now been replicated by independent research teams and found to be superior to prominent alternative theories. bSCT has led to the development of a new theory-driven instant assessment system (iAx) that improves treatment effectiveness and can be incorporated into routine clinical practice. Evaluating the implementation of iAx in specialist addiction treatment services is the focus of Associate Professor Gullo's MRFF Translating Research into Practice (TRIP) Fellowship.

Selected NHMRC ECF publications:


- **Gullo, M. J.**, Loxton, N. J., Price, T., Voisey, J., Young, R. M., & Connor, J. P. (2017). A laboratory model of impulsivity and alcohol use in late adolescence. *Behaviour Research and Therapy*, *97*, 52-63.
- Patton, K. A., Connor, J. P., Sheffield, J., Wood, A., & **Gullo, M. J.** (2019). Additive effectiveness of mindfulness meditation to a school-based brief cognitive-behavioral alcohol intervention for adolescents. *Journal of Consulting and Clinical Psychology*, *87*(5), 407-421.
- **Gullo, M. J.**, & Potenza, M. N. (2014). Impulsivity: Mechanisms, moderators and implications for addictive behaviors. *Addictive Behaviors*, *39*(11), 1543-1546.
- Leamy, T. E., Connor, J. P., Voisey, J., Young, R. M., & **Gullo, M. J.** (2016). Alcohol misuse in emerging adulthood: Association of dopamine and serotonin receptor genes with impulsivity-related cognition. *Addictive Behaviors*, *63*, 29-36.
- **Gullo, M. J.**, St. John, N., Young, R. M., Saunders, J. B., Noble, E. P., & Connor, J. P. (2014). Impulsivity-related cognition in alcohol dependence: Is it moderated by DRD2/ANKK1 gene status and executive dysfunction? *Addictive Behaviors*, *39*(11), 1663-1669.
- Patton, K., Connor, J. P., Rundle-Thiele, S., Dietrich, T., Young, R. M., & **Gullo, M. J.** (2018). Measuring adolescent drinking-refusal self-efficacy: Development and validation of the Drinking Refusal Self-Efficacy Questionnaire-Shortened Adolescent version (DRSEQ-SRA). *Addictive Behaviors*, *81*, 70-77.
- Patton, K. A., Connor, J. P., Rundle-Thiele, S., Dietrich, T., Young, R. M., & **Gullo, M. J.** (2018). Validation of the Adolescent Drinking Expectancy Questionnaire and development of a short form. *Drug and Alcohol Review*, *37*(3), 396-405.



Dr. Gary Chan

Dr. Gary Chan is a NHMRC Emerging Leadership Fellow (2020-2025). Tobacco is the deadliest consumer product in human history. It is also the leading preventable cause of premature death in Australia and globally. Over 7 million people die from smoking related diseases annually worldwide. If this trend continues, over 1 billion individuals will die from smoking by 2100.

Vaping devices (VDs) hold the promise to reverse this trend and save millions of lives as cessation aids and less harmful substitutes for tobacco. However, their rapid increase in popularity, particular among young people in many countries, has raised concerns that their use will renormalize smoking, creating a new generation of those addicted to nicotine.



... [vaping devices] their rapid increase in popularity, particular among young people in many countries, has raised concerns that their use will renormalize smoking...

Because of a lack of evidence for their benefits and harms, governments around the world have adopted very different approaches to VDs regulation, from completely banning them (e.g. Singapore) to embracing them as legitimate consumer products (e.g. the UK).

In addition, there is an emerging trend of using other liquified illicit substances (e.g. cannabis and hallucinogens) in VDs purchased from online cryptomarkets. The VD industry is growing rapidly, and our current understanding of VDs is insufficient to guide policy.

The goal of Dr. Chan's fellowship is to overcome the gaps in our knowledge regarding VDs and to inform future policies.

The specific aims are to

- Investigate how the differences and changes in regulatory environments in UK, Australia, Canada and US influence how smokers use VDs, and quantify the impact of VDs on smoking cessation and reduction.
- Understand how young people use VDs and the potential health and behavioral consequences.
- Track the evolution of VD use among young people, including trends and patterns of use, and what substances other than nicotine young people use with VDs.
- Systematically examine what substances are available for purchase online and estimate the amount of illicit substances for vaping sold to Australians.

To achieve these aims, Dr. Chan has recruited two PhD students in early 2020, and will use cutting-edge statistical methods on several large epidemiological dataset collected from over 100000 individuals in UK, Australia, Canada and US.

Professor John Saunders Reflections: Coming of Age: 10 years of CYSAR

CYSAR asked foundation Honorary Professor John Saunders for his thoughts on CYSAR's progress over the past 10 years and future challenges. John's published contributions over the same period are also highlighted.

Reply: Professor John Saunders

This year marks the Tenth Anniversary of the foundation of the Centre for Youth Substance Abuse Research (CYSAR) in 2008, and therefore its “coming of age” as a research centre. Its position as a leading contributor to knowledge and practice in the addictions area and particularly in youth has been consolidated by its winning national status with the award of a Commonwealth of Australia Centre Grant.

What are the ways in which CYSAR can further develop its national and international reputation? Here are some thoughts.

Firstly, keep abreast of changes in the wider community, in terms of what psychoactive substances are in vogue especially in young people. What role does substance use have in youth? What is its functional value? What harms are regarded as important? What other addictive disorders are becoming prominent? Here I draw attention to the rapid increase in online activities such as gaming, and gambling. When social networking was introduced, benefit for all was assumed, but it has become a means of social exclusion and bullying for many.

As these technologies become more powerful and pervasive, their capacity for harm becomes ever greater.

Secondly, develop and keep abreast of new concepts and theories of substance use and addictive behaviours. How much of an “addictive progression” is seen in young people compared with their older counterparts?

Thirdly, adapt and develop advances in technologies, including biostatistical techniques.

Fourthly, and of key importance in its consolidation as research centre, provide a nexus whereby researchers and practitioners in the public health and clinical fields can interact productively.

Substance use is an ever changing phenomenon and it is essential for all of us involved to keep abreast of changes in the types of substances which predominate but also on how they are used, where and who with and the legislation that applies to substance use as time goes by. We need to be aware of the developing technologies – a good example is electronic cigarettes and vaping – but also the revolution in communication technologies and especially social media.

My own career extends from when the main substances of consequence were alcohol and tobacco, the latter overwhelmingly in the form of cigarette smoking. Of course alcohol has been an integral part of Western society for some thousands of years and tobacco for several hundred years; we have a familiarity with them. In response to their acknowledged harms, legislation has sought to reduce their level of use and consequent harms.

One of the great success stories of modern Australia is the reduction in cigarette smoking from over 75% of men in late 1940's to 17% nowadays.

More of course can be done but one should never forget about one of the great public health success stories of the modern world, in which Australia has been a leader.

Over my career and prior to that when I was a student, I witnessed phases of popularity of various substances, the 1960s saw the use of cannabis (marijuana) on a widespread basis among young people, at a time when there was what was described as a “social” revolution.


Cannabis was and remains a drug which many young people took up as emblematic of their generation and it was strongly associated with the political protest movements of the 1960's and 1970's. Subsequently MDMA (Ecstasy) gained prominence as a party drug and several substances have been adopted as a mark of difference from the older generation. More recently drug use has been intertwined with dance parties and music festivals, which have become increasingly popular with young people.

A key issue for CYSAR is to engage with young people as to how they view their preferred substances and how they wish to protect themselves from adverse consequences. Engagement of CYSAR with representative groups of young people, as has been a feature of CYSAR's work from its outset, is a vital aspect of ensuring the relevance of its initiatives to the modern world. The role of politicians is to allow these processes to take place and to be respectful of the views of young people and what initiatives they think are worthwhile.

Understanding of the available technologies is also vital as technologies can have a major impact on substance use, these are of two types. The first are delivery mechanisms and we recognise two classic examples.

The first is the development of the hypodermic syringe, which was introduced into medical practice in the 1870's and was the way in which an epidemic of injecting drug use was fomented. Subsequently of course it has been an important tool in the form of the availability of sterile injecting equipment to prevent the spread of HIV and also other blood borne viruses such as Hepatitis C. Another technology but one without a therapeutic component was the invention of the automated cigarette rolling machine in 1890. This laid the ground for an epidemic of smoking and smoking-related diseases such as lung cancer and coronary artery disease. Technologies these days more commonly refer to social media ones and ones such as smart phones to enable almost instantaneous involvement with on-line games and on-line gambling.

What do we learn from this? Firstly, substance use is ever changing and it is incumbent on CYSAR to be aware of and respond to these changes and the environments in which substance use commonly takes place. One key current issue is the safety of young people in dance parties and music festivals and investigation of different approaches to ensure safety contributing to best practice guidelines for such venues may be a key line of investigation.



... investigation of different approaches to ensure safety contributing to best practice guidelines for such venues may be a key line of investigation.

Secondly what are the key lines of investigation for both policy, psychological and pharmacological interventions? There is much interest in “third generation” psychological interventions, these such as acceptance of commitment therapy have been developed for other disorders and issues and have been adapted for substance use, relapse prevention and harm reduction, but in this area the evidence base is still limited. To what extent can brief interventions be applied in the environments mentioned above? Brief interventions have most application when directed to hazardous and harmful alcohol consumption and provided in health care settings. Can they be applied to the use of, say, ecstasy, in dance parties and music festivals? At least that is a research question. More broadly it would seek to engage young people in health oriented thinking environments which are attractive to them.

Pharmacological interventions have been pursued over more than a generation. For alcohol among adults with alcohol dependence (most of the participants being aged over 30), there are several established medications. For opiates the most effective treatments for most people with opioid dependence most of the time are the agonist pharmacotherapies, buprenorphine and methadone.

A generation ago they were controversial, with their antagonists stating that they merely perpetuated the addiction.

The evidence that they reduced harm, including reductions in mortality of 80% or more in controlled studies swung opinion overwhelmingly in their favour. With regard to psychostimulants, addiction to these has been termed “an impervious condition” to medications. Can we learn from the experience in opiate agonist treatment to develop appropriate agonist approaches for psychostimulant dependence, which would be similarly attractive to those affected? More work on modafinil and lisdexamfetamine and other stimulants with a flat pharmacological profile would be appropriate.

The Internet has provided instantaneous information and communications, but there are concerns about the broader use of social communications and their related technologies. Concerns include cyber bullying, texting with pornographic content or visuals, the use of social networks to exclude individuals and the replacement of “real life” friendships with contacts who have been made exclusively on-line.

... substance use is ever changing and it is incumbent on CYSAR to be aware of and respond to these changes and the environments in which substance use commonly takes place.

What was originally intended to be a tool to enhance social communications and connectedness has now often been subverted to a means of abusing and belittling others and having a detrimental effect on their health and welfare.

With the knowledge that CYSAR has accumulated in electronic interventions, working out the balance of the positives and negatives of social communications could be an important line of research to complement the studies of substance use and other addictive behaviours that are presently being undertaken.

The final aspect of CYSAR's role is to provide an environment where researchers and practitioners, including those involved with preventive initiatives, can interact productively. I have found a collegial environment whenever I have visited CYSAR and its move to The University of Queensland St Lucia campus has enhanced the interaction with relevant academic departments. CYSAR has networks of young people and another vital nexus is with that connection with young people in schools and work places. These networks provide valuable opportunities to present CYSAR's work and at the same time to seek input and involvement of young people in the development of CYSAR's lines of investigation and overall strategic direction.

I look forward to the next 10 years of CYSAR's work!



John B. Saunders

Professor Saunders' publications since foundation of CYSAR (2008) to 2018

Books

1. Latt NC, Conigrave KM, Saunders JB, Marshall EJ, Nutt D (Eds). (2009). *Addiction Medicine*. Oxford: Oxford University Press.
2. Saunders JB, Rey JM (Eds). (2011). *Young People and Alcohol: Impact, Policy, Prevention, Treatment*. Oxford, UK: Wiley-Blackwell.
3. Saunders JB, Conigrave KM, Latt NC, Nutt DJ, Marshall EJ, Ling W, Higuchi S (Eds). (2016). *Addiction Medicine (2nd ed)*. Oxford: Oxford University Press.
4. Saunders JB, Schuckit MA, Sirovatka PJ, Regier DA (Eds.). (2007). *Diagnostic Issues in Substance Use Disorders: Refining the Research Agenda for DSM-V*. Arlington, Virginia: American Psychiatric Association.

Book chapters

5. Stockley C, Saunders JB. (2010). The biology of intoxication. In A Fox, M MacAvoy (Eds), *Expressions of Drunkenness* (pp. 13-52). New York: Routledge.
6. Saunders JB. (2011). The biology of alcohol and alcohol misuse. In JB Saunders, JM Rey (Eds), *Young People and Alcohol: Impact, Policy, Prevention, Treatment* (pp. 47-65). Oxford, UK: Wiley-Blackwell.
7. Saunders JB, Anderson P, Rey JM. (2011). Alcohol policy and the prevention of harm in young people. In JB Saunders, JM Rey (Eds), *Young People and Alcohol: Impact, Policy, Prevention, Treatment* (pp. 105-121). Oxford, UK: Wiley-Blackwell.
8. Saunders JB, Latt NC. (2011). The prevention of alcohol problems. In H Ghodse, H Herrman, M Maj, N Sartorius (Eds), *Substance Abuse: Evidence and Experience in Psychiatry* (pp. 125-145). Oxford: Wiley-Blackwell.
9. Saunders JB, Latt NC. (2011). Diagnosis and classification of substance use disorders. In BA Johnson (Ed), *Addiction Medicine: Science and Practice* (pp. 95-113). New York: Springer.
10. Saunders JB. (2015). Alcohol and other substance misuse. In J Neuberger, A DiMartini (Eds), *Alcohol Abuse and Liver Disease* (pp. 35-45). Oxford: Wiley-Blackwell.

11. Saunders JB. (2015). The nature of alcohol use disorders. In A McCune (Ed), ABC of Alcohol (5th ed, pp. 19-24). Chichester, UK: John Wiley.

12. Saunders JB. (2015). The detection of alcohol use disorders. In A McCune (Ed), ABC of Alcohol (5th ed, pp. 25-32). Chichester, UK: John Wiley.

13. Saunders JB, Latt NC. (2015). Screening and early interventions: an introduction. In N El-Guebaly, G Carra, M Galanter (Eds), Textbook of Addiction Treatment: International Perspectives (pp. 161-166). New York: Springer.

14. Saunders JB, Latt NC. (2015). Diagnostic definitions, criteria and classification of substance use disorders. In N El-Guebaly, G Carra, M Galanter (Eds), Textbook of Addiction Treatment: International Perspectives (pp. 167-189). New York: Springer.

15. Saunders JB, Latt NC. (2015). Screening, early detection and brief intervention for alcohol use disorders. In N El-Guebaly, G Carra, M Galanter (Eds), Textbook of Addiction Treatment: International Perspectives (pp. 191-206). New York: Springer.

16. Saunders JB. (2016). Alcohol use disorders. In P Haber, C Day, M Farrell (Eds), Addiction Medicine: Principles and Practice (pp. 296-315). IP Communications: Melbourne.

17. Connor JP, Feeney GFX, Kelly AB, Saunders JB. (2017). Polysubstance abuse. In K Wolff, J White, S Karch (Eds), SAGE Handbook of Drug and Alcohol Studies (pp. 283-306). Thousand Oaks: Sage.

18. Saunders JB, Connor JP, Feeney GFX. (2017). Gamma-hydroxybutyric Acid (GHB) and analogues Gamma-butyrolactone (GBL) 1,4-butanediol (1,4-BD). In K Wolff, J White, S Karch (Eds), SAGE Handbook of Drug and Alcohol Studies (pp. 271-282). Thousand Oaks: Sage.

19. Saunders JB, Latt NC. (2019 in press). Diagnosis and classification of substance use disorders. In BA Johnson (Ed), Addiction Medicine: Science and Practice (2nd ed). New York; Berlin: Springer.

Peer reviewed journal articles

20. Connor JP, Young RMcD, Saunders JB, Lawford BR, Ho R, Ritchie TL, Noble EP. (2008). The A1 allele of the D2 dopamine receptor gene region, alcohol expectancies and drinking refusal self-efficacy are associated with alcohol dependence severity. *Psychiatry Research*, 160, 94-105.

- 21.** Kypri K, Langley JD, Saunders JB, Cashell-Smith ML, Herbison P. (2008). Randomized controlled trial of web-based alcohol screening and brief intervention in primary care. *Archives of Internal Medicine*, 168, 530-536.
- 22.** Saunders JB. (2008). Addiction and addiction journals. *Drug and Alcohol Review*, 27, 577-578.
- 23.** Kaner EF, Dickinson HO, Beyer F, Pienaar E, Schlesinger C, Campbell F, Saunders JB, Burnand B, Heather N. (2009). The effectiveness of brief alcohol interventions in primary care settings: a systematic review. *Drug and Alcohol Review*, 28, 301-323.
- 24.** Lapworth K, Dawe S, Davis P, Kavanagh D, Young RMcD, Saunders JB. (2009). Impulsivity and positive psychotic symptoms influence hostility in methamphetamine users. *Addictive Behaviors*, 34, 380-385.
- 25.** Tabakoff B, Saba L, Printz M, Flodman P, Hodgkinson C, Goldman D, Koob G, Richardson HN, Kechris K, Bell RL, Hübner N, Heinig M, Pravenec M, Mangion J, Legault L, Dongier M, Conigrave KM, Whitfield JB, Saunders JB, Grant B, Hoffman PL, WHO IISBRA Study on Trait Markers of Alcoholism. (2009). Genetical genomic determinants of alcohol consumption in rats and humans. *BMC Biology*, 7, 70.
- 26.** White J, Bell J, Saunders JB, Williamson P, Makowska M, Farquharson A, Beebe KL. (2009). Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. *Drug and Alcohol Dependence*, 103, 37-43.
- 27.** Kypri K, McCambridge J, Cunningham JA, Vater T, Bowe S, De Graaf B, Saunders JB, Dean J. (2010). Web-based alcohol screening and brief intervention for Maori and non-Maori: the New Zealand e-SBINZ trials. *BMC Public Health*, 10, 781.
- 28.** Dean AJ, Saunders JB, Bell J. (2011). Heroin use, dependence, and attitudes to treatment in non-treatment-seeking heroin users: a pilot study. *Substance Use and Misuse*, 46, 417-425.
- 29.** Dua T, Barbui C, Clark N, Fleischmann A, Poznyak V, van Ommeren M, Yasamy MT, Ayuso-Mateos JL, Birbeck GL, Drummond C, Freeman M, Giannakopoulos P, Levav I, Obot IS, Omigbodun O, Patel V, Phillips M, Prince M, Rahimi-Movaghar A, Rahman A, Sander JW, Saunders JB, Servili C, Rangaswamy T, Unutzer J, Ventevogel P, Vijayakumar L, Thornicroft G, Saxena S. (2011). Evidence-based guidelines for mental, neurological, and substance use disorders in low- and middle-income countries: summary of WHO recommendations. *PLoS Medicine*, 8, e1001122.

- 30.** Kavanagh DJ, Trembath M, Shockley N, Connolly J, White A, Isailovic A, Young RMCD, Saunders JB, Byrne GJ, Connor J. (2011). The DrugCheck Problem List: a new screen for substance use disorders in people with psychosis. *Addictive Behaviors*, 36, 927-932.
- 31.** Saunders JB, Cottler LB. (Eds) (2011). Section papers: Addictive Disorders. *Current Opinion in Psychiatry*, 24, 181-214.
- 32.** Saunders JB, Room R. (2012). Enhancing the ICD system in recording alcohol's involvement in disease and injury. *Alcohol and Alcoholism*, 47, 216-218.
- 33.** Johnson NA, Kypri K, Saunders JB, Saitz R, Attia J, Dunlop A, Doran C, McElduff P, Wolfenden L, McCambridge J. (2013). The hospital outpatient alcohol project (HOAP): protocol for an individually randomized, parallel-group superiority trial of electronic alcohol screening and brief intervention versus screening alone for unhealthy alcohol use. *Addiction Science & Clinical Practice*, 8, 14.
- 34.** Kypri K, McCambridge J, Vater T, Bowe SJ, Saunders JB, Cunningham JA, Horton NJ. (2013). Web-based alcohol intervention for Maori university students: double-blind, multi-site randomized controlled trial. *Addiction*, 108, 331-338.
- 35.** Quek LH, Chan GC, White A, Connor JP, Baker PJ, Saunders JB, Kelly AB. (2013). Concurrent and simultaneous polydrug use: latent class analysis of an Australian nationally representative sample of young adults. *Frontiers in Public Health*, 1, 61.
- 36.** Saunders JB. (2013). The concept of substance use disorders. A commentary on 'Defining substance use disorders: do we really need more than heavy use' by Rehm et al. *Alcohol and Alcoholism*, 48, 644-645.
- 37.** White A, Chan GC, Quek LH, Connor JP, Saunders JB, Baker P, Brackenridge C, Kelly AB. (2013). The topography of multiple drug use among adolescent Australians: findings from the National Drug Strategy Household Survey. *Addictive Behaviors*, 38, 2068-2073.
- 38.** Gullo MJ, St John N, Young RMCD, Saunders JB, Noble EP, Connor JP. (2014). Impulsivity-related cognition in alcohol dependence: Is it moderated by DRD2/ANKK1 gene status and executive dysfunction? *Addictive Behaviors*, 39, 1663-1669.
- 39.** Johnson NA, Kypri K, Latter J, McElduff P, Saunders JB, Saitz R, Attia J, Dunlop A, Doran C, Wolfenden L, McCambridge J. (2014). Prevalence of unhealthy alcohol use in hospital outpatients. *Drug and Alcohol Dependence*, 144, 270-273.

- 40.** Kelly AB, Chan GC, White A, Saunders JB, Baker PJ, Connor JP. (2014). Is there any evidence of changes in patterns of concurrent drug use among young Australians 18-29 years between 2007 and 2010? *Addictive Behaviors*, 39, 1249-1252.
- 41.** Kypri K, Vater T, Bowe SJ, Saunders JB, Cunningham JA, Horton NJ, McCambridge J. (2014). Web-based alcohol screening and brief intervention for university students: a randomized trial. *JAMA*, 311, 1218-1224.
- 42.** Hides L, Dawe S, McKetin R, Kavanagh DJ, Young RMcD, Teesson M, Saunders JB. (2015). Primary and substance-induced psychotic disorders in methamphetamine users. *Psychiatry Research*, 226, 91-96.
- 43.** Johnson NA, Kypri K, Latter J, McElduff P, Attia J, Saitz R, Saunders JB, Wolfenden L, Dunlop A, Doran C, McCambridge J. (2015). Effect of telephone follow-up on retention and balance in an alcohol intervention trial. *Preventive Medicine Reports*, 2, 746-749.
- 44.** Mann K, Fauth-Buhler M, Higuchi S, Potenza MN, Saunders JB. (2016). Pathological gambling: a behavioral addiction. *World Psychiatry*, 15, 297-298.
- 45.** McKetin R, Dawe S, Burns RA, Hides L, Kavanagh DJ, Teesson M, Young RMcD, Voce A, Saunders JB. (2016). The profile of psychiatric symptoms exacerbated by methamphetamine use. *Drug and Alcohol Dependence*, 161, 104-109.
- 46.** Billieux J, King DL, Higuchi S, Achab S, Bowden-Jones H, Hao W, Long J, Lee HK, Potenza MN, Saunders JB, Poznyak V. (2017). Functional impairment matters in the screening and diagnosis of gaming disorder. *Journal of Behavioral Addictions*, 6, 285-289.
- 47.** Saunders JB. (2017). Substance use and addictive disorders in DSM-5 and ICD 10 and the draft ICD 11. *Current Opinion in Psychiatry*, 30, 227-237.
- 48.** Saunders JB, Degenhardt L, Farrell M. (2017). Excessive gambling and gaming: addictive disorders? *Lancet Psychiatry*, 4, 433-435.
- 49.** Saunders JB, Hao W, Long J, King DL, Mann K, Fauth-Buhler M, Rumpf HJ, Bowden-Jones H, Rahimi-Movaghar A, Chung T, Chan E, Bahar N, Achab S, Lee HK, Potenza M, Petry N, Spritzer D, Ambekar A, Derevensky J, Griffiths MD, Pontes HM, Kuss D, Higuchi S, Mihara S, Assangangkornchai S, Sharma M, Kashef AE, Ip P, Farrell M, Scafato E, Carragher N, Poznyak V. (2017). Gaming disorder: its delineation as an important condition for diagnosis, management, and prevention. *Journal of Behavioral Addictions*, 6, 271-279.

- 50.** Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. (2018). Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis. *Drug and Alcohol Dependence*, 191, 234-258.
- 51.** Johnson NA, Kypri K, Latter J, Dunlop A, Brown A, Saitz R, Saunders JB, Attia J, Wolfenden L, Doran C, McCambridge J. (2018). Effect of electronic brief intervention on uptake of specialty treatment in hospital outpatients with likely alcohol dependence: Pilot randomized trial and qualitative interviews. *Drug and Alcohol Dependence*, 183, 253-260.
- 52.** Johnson NA, Kypri K, Saunders JB, Saitz R, Attia J, Latter J, McElduff P, Dunlop A, Doran C, Wolfenden L, McCambridge J. (2018). Effect of electronic screening and brief intervention on hazardous or harmful drinking among adults in the hospital outpatient setting: A randomized, double-blind, controlled trial. *Drug and Alcohol Dependence*, 191, 78-85.
- 53.** Kaner EF, Beyer FR, Muirhead C, Campbell F, Pienaar ED, Bertholet N, Daepfen JB, Saunders JB, Burnand B. (2018). Effectiveness of brief alcohol interventions in primary care populations. *Cochrane Database of Systematic Reviews*, 2, CD004148.
- 54.** King DL, Adair C, Saunders JB, Delfabbro PH. (2018). Clinical predictors of gaming abstinence in help-seeking adult problematic gamers. *Psychiatry Research*, 261, 581-588.
- 55.** King DL, Potenza M, Billieux J, Saunders JB, Stein DJ, Delfabbro PH, Gaming Industry Response Consortium. (2018). Comment on the global gaming industry's statement on ICD-11 gaming disorder: a corporate strategy to disregard harm and deflect social responsibility? *Addiction*, 113, 2145-2146.
- 56.** McKetin R, Hides L, Kavanagh DJ, Saunders JB, Dawe S. (2018). First psychotic episode risk markers for primary psychosis amongst people who use methamphetamine. *Schizophrenia Research*, 199, 456-457.
- 57.** Rumpf HJ, Achab S, Billieux J, Bowden-Jones H, Carragher N, Demetrovics Z, Higuchi S, King DL, Mann K, Potenza M, Saunders JB, Abbott M, Ambekar A, Aricak OT, Assanangkornchai S, Bahar N, Borges G, Brand M, Chan EM, Chung T, Derevensky J, Kashef AE, Farrell M, Fineberg NA, Gandin C, Gentile DA, Griffiths MD, Goudriaan AE, Grall-Bronnec M, Hao W, Hodgins DC, Ip P, Kiraly O, Lee HK, Kuss D, Lemmens JS, Long J, Lopez-Fernandez O, Mihara S, Petry NM, Pontes HM, Rahimi-Movaghar A, Rehbein F, Rehm J, Scafato E, Sharma M, Spritzer D, Stein DJ, Tam P, Weinstein A, Wittchen HU, Wolfing K, Zullino D,

Poznyak V. (2018). Including gaming disorder in the ICD-11: the need to do so from a clinical and public health perspective. *Journal of Behavioral Addictions*, 7, 556-561.

58. Saunders JB, Cottler LB. (2018). Editorial: International collaborative research in the addictions. *Current Opinion in Psychiatry*, 31, 283-286.

59. Saunders JB, Peacock A, Degenhardt L. (2018). Alcohol Use Disorders in the draft ICD-11, and how they compare with DSM-5. *Current Addiction Reports*, 5, 257-264.

60. Stein DJ, Billieux J, Bowden-Jones H, Grant JE, Fineberg N, Higuchi S, Hao W, Mann K, Matsunaga H, Potenza MN, Rumpf HM, Veale D, Ray R, Saunders JB, Reed GM, Poznyak V. (2018). Balancing validity, utility and public health considerations in disorders due to addictive behaviours. *World Psychiatry*, 17, 363-364.

61. Beyer FR, Campbell F, Bertholet N, Daepfen JB, Saunders JB, Pienaar ED, Muirhead CR, Kaner EFS. (2019). The Cochrane 2018 review on brief interventions in primary care for hazardous and harmful alcohol consumption: a distillation for clinicians and policy makers. *Alcohol and Alcoholism*, 54, 417-427.

62. Rafiemanesh H, Yazdani K, Nedjat S, Noroozi A, Saunders JB, Mojtabai R, Rahimi-Movaghar A. (2019). Alcohol Use Disorders Identification Test (AUDIT): validation of the Persian version in an Iranian population. *Alcohol*, August 14, 10.1016/j.alcohol.2019.1008.1002.

63. Reed GM, First MB, Kogan CS, Hyman SE, Gureje O, Gaebel W, Maj M, Stein DJ, Maercker A, Tyrer P, Claudino A, Garralda E, Salvador-Carulla L, Ray R, Saunders JB, Dua T, Poznyak V, Medina-Mora ME, Pike KM, Ayuso-Mateos JL, Kanba S, Keeley JW, Khoury B, Krasnov VN, Kulygina M, Lovell AM, de Jesus Mari J, Maruta T, Matsumoto C, Rebello TJ, Roberts MC, Robles R, Sharan P, Zhao M, Jablensky A, Udomratn P, Rahimi-Movaghar A, Rydelius PA, Bahrer-Kohler S, Watts AD, Saxena S. (2019). Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. *World Psychiatry*, 18, 3-19.

64. Saunders JB, Degenhardt L, Reed GM, Poznyak V. (2019). Alcohol Use Disorders in ICD-11: past, present, and future. *Alcoholism, Clinical and Experimental Research*, 43, 1617-1631.

2018 Research Grants and Contracts

Chief Investigators	Amount Awarded	Years	Funding Source	Type of Grant	Title
Connor, Hides	\$3.5M	2018 submitted, awarded for 2019-2022	Drug and Alcohol Program, Commonwealth Department of Health	Alcohol and Other Drug Research Centre of Excellence	Understanding, preventing and treating youth substance abuse
Gullo	\$181,066	2018 awarded for 2019-2020	Medical Research Future Fund Next Generation Clinical Researchers Program	Translating Research Into Practice Fellowship	iAx: Instant assessment and personalised feedback in alcohol use disorder
Patton, Moreno-Betancur, Butterworth, Hall , Borschmann, Moschion, Moran, Campbell	\$1,143,946	2018 submitted; awarded for 2019-2022	NHMRC	Project Grant	Common mental and substance use disorders in a 28-year follow-up of a community cohort: identification of preventive strategies from adolescence to early midlife
Connor , Clark, Feeney, Gullo , Holtman	\$69,585	2018 submitted; awarded for 2019-2020	Metro South Health Research Support Scheme	Project Grant	When drugs don't work: Tailored behavioural intervention for alcoholic hepatitis
Gullo , Connor , Feeney	\$24,920	2018 submitted; awarded for 2019-2020	Metro South Health Research Support Scheme	Innovation Grant	Enhancing assessment and progress monitoring in alcohol use disorder treatment
Hammond, Hall , Pacula, George, Rehm, Werb, Boudreau, Wadsworth, Leos-Toro, Porath-Waller, Elliot	CAD \$1,514,700	2018-2023	CIHR (Canadian Institutes of Health Research) - Federal funding agency	Project Grant	Cannabis legalization: impact on prevalence and risk behaviours among young people in Canada
Berridge, Hall , Fairchild, Bayer	GBP29,414	2018	Wellcome Trust	Cross National Project	Electronic cigarettes: history, evidence and policy
Hall	€28,000	2018	European Monitoring Centre for Drugs and Drug Addiction	Invited Tender	Technical review - use of cannabis for medicinal purposes
Hall	€35,000	2018	European Monitoring Centre for Drugs and Drug Addiction	Invited Tender- renewal	Scientific writing support for EMCDDA Scientific Publication
Chan	USD \$1,000	2018	College on Problems of Drug Dependence	Early Career Researcher Travel Award- CPDD annual meeting	To attend leading North American annual scientific meeting in the field (only 4 Australian recipients in 2018)

Continuing Grants

Chief Investigators	Amount Awarded	Years	Funding Source	Type of Grant	Title
Connor, Hides	\$2,315,000	2017-2019	Drug and Alcohol Program, Commonwealth Department of Health	Alcohol and Other Drug Research Centre of Excellence	Understanding, preventing and treating youth substance abuse
Connor , on behalf of CYSAR	\$2,000,000	2013-2018	UQef The University of Queensland Endowment Fund	Gift	Gift to the Centre for Youth Substance Abuse Research from Graeme Wood and Andrew Brice
Whiteford, Degenhardt, Pirkis, Eagar, Andrews, Head, Gunn, Mihalopoulos, Hall , Patton	\$2,442,370	2012-2018	NHMRC	Centres of Research Excellence	Evidence-based mental health planning: translating evidence into policy and services
Kavanagh , Graves, Connor , Hides , Gullo , Connolly, Andrade, May	\$895,032	2016-2019	NHMRC	Project Grant	A new, low-cost e-health treatment for Alcohol Use Disorder using mental imagery
Hides, Kavanagh , Connor , Daghli, Cotton, Barendregt, Witkiewitz, Young, White	\$702,461	2012-2018	NHMRC	Targeted Call for Mental Health Research	Brief telephone interventions for reducing future alcohol use and related harm in young people accessing emergency departments
Borland, Gartner, Hall , Yong, Mundy, Courtney	\$1,603,159	2016-2020	NHMRC	Project Grant	Understanding the impacts of Vaporised Nicotine Products on smoking in Australia

Continuing Grants

Chief Investigators	Amount Awarded	Years	Funding Source	Type of Grant	Title
Mueller, Thai, Gartner, Prichard, Hall , Lai, Jiang, Kirkbride, Bruno, Ort, Covaci, Carter, Lubman, Lloyd, Udi, Connolly	\$603,798	2015-2020	ARC	Linkage Projects	Estimating per capita use and release of chemicals by wastewater analysis
Rundle-Thiele, Arli, Kubacki, Connor, Gullo , Percy	\$234,000 plus \$162,000 to partner	2016-2018	ARC	Linkage Project in partnership with Catholic Education	Changing Australian drinking: A comprehensive social marketing program
Gallagher, Connor , Loveday, Ballantyne	\$191,000 plus \$200,000 to partner	2016-2019	ARC	Linkage Project in partnership with Queensland Health	Active and interactive analysis of prescription data for harm minimisation
Chan	\$197,818	2016-2019	UQ	UQ Fellowships - Early Career Researcher stream	Pathways to multiple substance use: informing the next generation of prevention science (mentored by A/Professor Kelly)
Chan	\$33,000	2017-2018	UQ	Early Career Researcher Grant	Informing future policies on cannabis in Australia. Lessons from new trends in the USA and from the history of tobacco control

2018 Research Publications

2018 Full Peer Reviewed Manuscripts

1. Adewumi A, Hollingworth S, Maravilla J, **Connor JP**, Alati R. Prescribed dose of opioids and overdose: a systematic review and meta-analysis of unintentional pre-prescription opioid overdose. *CNS Drugs* 2018; 32: 101-16.
2. Adewumi A, Staatz C, Hollingworth S, **Connor JP**, Alati R. Prescription opioid fatalities: examining why the healer could be the culprit. *Drug Safety* 2018; 41: 1023-33.
3. Ahmadvand A, Drennan J, Burgess J, Clark M, **Kavanagh DJ**, Burns K, Howard S, Kelly F, Campbell C, Nissen L. Novel augmented reality solution for improving health literacy around antihypertensives in people living with type 2 diabetes mellitus: protocol of a technology evaluation study. *BMJ Open* 2018; 8: 6.
4. Alla K, Oprescu F, **Hall WD**, Whiteford H, Head B, Meurk C. Can automated content analysis be used to assess and improve the use of evidence in mental health policy? A systematic review. *Systematic Reviews* 2018; 7: 16.
5. Andersson E, Holmes EA, **Kavanagh DJ**. Innovations in digital interventions for psychological trauma: harnessing advances in cognitive science. *mHealth* 2018; 4: 47.
6. Bailey K, Baker A, McElduff P, Kay-Lambkin F, **Kavanagh DJ**. Do outcomes of cognitive-behaviour therapy for co-occurring alcohol misuse and depression differ for participants with symptoms of posttraumatic stress? *Journal of Mental Health* 2018 submitted: 10.1080/09638237.2019.1581354.
7. Barnett A, **Hall WD**, Fry C, Dilkes-Frayne E, Carter A. Drug and alcohol treatment providers' views about the disease model of addiction and its impact on clinical practice: a systematic review. *Drug and Alcohol Review* 2018; 37: 697-720.
8. Barnett A, **Hall WD**, Fry CL, Dilkes-Frayne E, Carter A. Implications of treatment providers' varying conceptions of the disease model of addiction: a response. *Drug and Alcohol Review* 2018; 37: 729-30.
9. Berridge V, **Hall WD**. *Addiction Lives*: Wayne Hall. *Addiction* 2018; 113: 564-7.
10. Birrell L, Newton N, Slade T, Chapman C, Mewton L, McBride N, **Hides L**, Chatterton M, Allsop S, Healy A, Mather M, **Quinn C**, Mihalopoulos C, Teesson M. Evaluating the long-term effectiveness of school-based depression, anxiety, and substance use prevention into young adulthood: protocol for the Climate School Combined Study. *JMIR Research Protocols* 2018; 7: 13.
11. Bruno R, Edirisinghe M, **Hall WD**, Mueller J, Lai FY, O'Brien J, Thai P. Association between purity of drug seizures and illicit drug loads measured in wastewater in a South East Queensland catchment over a six year period. *Science of the Total Environment* 2018; 635: 779-83.
12. Bulley A, Miloyan B, Pepper G, **Gullo MJ**, Henry J, Suddendorf T. Cuing both positive and negative episodic foresight reduces delay discounting but does not affect risk taking. *Quarterly Journal of Experimental Psychology* 2018; December 3: 10.1177/1747021818819777.
13. Butterworth P, Becker D, Degenhardt L, **Hall WD**, Patton G. Amphetamine use in the fourth decade of life: social profiles from a population-based Australian cohort. *Drug and Alcohol Review* 2018; 37: 743-51.
14. Cairns A, **Kavanagh DJ**, Dark F, McPhail S. Comparing predictors of part-time and no vocational engagement in youth primary mental health services: a brief report. *Early Intervention in Psychiatry* 2018; 12: 726-9.
15. Campbell G, **Hall WD**, Degenhardt L, Dobbins T, Farrell M. Cannabis use and non-cancer chronic pain: Reply. *Lancet Public Health* 2018; 3: e469.
16. Campbell G, **Hall WD**, Nielsen S. What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review. *International Review of Psychiatry* 2018; 30: 91-106.

17. Campbell G, **Hall WD**, Peacock A, Lintzeris N, Bruno R, Larance B, Nielsen S, Cohen M, **Chan GCK**, Mattick R, Blyth F, Shanahan M, Dobbins T, Farrell M, Degenhardt L. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. *Lancet Public Health* 2018; 3: e341-e50.
18. Carah N, **Meurk C**, Males M, Brown J. Emerging social media 'platform' approaches to alcohol marketing: a comparative analysis of the activity of the top 20 Australian alcohol brands on Facebook (2012-2014). *Critical Public Health* 2018; 28: 70-80.
19. **Chan GCK**, Butterworth P, Becker D, Degenhardt L, Stockings E, **Hall WD**, Patton G. Longitudinal patterns of amphetamine use from adolescence to adulthood: a latent class analysis of a 20-year prospective study of Australians. *Drug and Alcohol Dependence* 2018; August 27: 10.1016/j.drugalcdep.2018.08.042.
20. **Chan GCK**, Leung J, Gartner C, Yong HH, Borland R, **Hall WD**. Correlates of electronic cigarette use in the general population and among smokers in Australia - findings from a nationally representative survey. *Addictive Behaviors* 2018 submitted: 10.1016/j.add-beh.2019.02.012.
21. **Chan GCK**, Leung J, **Hall WD**. Non-medical use of pharmaceutical opioids with and without other illicit substances in Australia: prevalence and correlates. *Drug and Alcohol Review* 2018 accepted: 10.1111/dar.12893.
22. **Chan GCK**, Leung J, Kelly AB, **Connor JP**, Edward S, **Hall WD**, Degenhardt L, **Chiu V**, Patton G. Familial alcohol supply, adolescent drinking and early alcohol onset in 45 low and middle income countries. *Addictive Behaviors* 2018; 84: 178-85.
23. **Chan GCK**, Leung J, **Quinn C**, **Weier M**, **Hall WD**. Socio-economic differentials in cannabis use trends in Australia. *Addiction* 2018; 113: 454-61.
24. **Chan GCK**, Morphett K, Gartner C, Leung J, Yong HH, **Hall WD**, Borland R. Predicting vaping uptake, vaping frequency and ongoing vaping among daily smokers using longitudinal data from the International Tobacco Control (ITC) Four Country Surveys. *Addiction* 2018; December 21: 10.1111/add.14537.
25. Chapman A, Carter A, Kaplan J, Morphett K, **Hall WD**. Ethical guidelines for genetic research on alcohol addiction and its applications. *Kennedy Institute of Ethics Journal* 2018; 28: 1-22.
26. **Coates JM**, **Gullo MJ**, Feeney GFX, Young RM, **Connor JP**. A randomized trial of personalized cognitive-behavior therapy for Alcohol Use Disorder in a public health clinic. *Frontiers in Psychiatry* 2018; 9: 12.
27. **Coates JM**, **Gullo MJ**, Feeney GFX, Young RM, Dingle G, **Connor JP**. Alcohol expectancies pre-and post-alcohol use disorder treatment: clinical implications. *Addictive Behaviors* 2018; 80: 142-9.
28. Cochrane A, Dick B, King N, Hills A, **Kavanagh DJ**. Developing dimensions for a multicomponent multidisciplinary approach to obesity management: a qualitative study. *BMC Public Health* 2017; 17: 814.
29. **Connor JP**, **Hall WD**. Thresholds for safer alcohol use might need lowering. *Lancet* 2018; 391: 1460-1.
30. Coomber K, Zahnow R, Ferris J, Droste N, Mayshak R, Curtis A, Kypri K, **de Andrade D**, Grant K, Chikritzhs T, Room R, Jiang H, Taylor N, Najman J, Miller P. Short-term changes in nightlife attendance and patron intoxication following alcohol restrictions in Queensland, Australia. *BMC Public Health* 2018; 18: 5.
31. da Silva J, **Kavanagh DJ**, Belpaeme T, Taylor L, Beeson K, Andrade J. Experiences of a motivational interview delivered by a robot: qualitative study. *Journal of Medical Internet Research* 2018; 20: 12.

32. Dawson A, Michael J, Dilkes-Frayne E, **Hall WD**, Disanayaka N, Carter A. Capacity, control and responsibility in Parkinson's disease patients with impulse control disorders: views of neurological and psychiatric experts. *International Journal of Law and Psychiatry* 2018; April 19: 10.1016/j.ijlp.2018.04.003.
33. **de Andrade D**, Homel R, Mazerolle L. Boozy nights and violent fights: perceptions of environmental cues to violence and crime in licensed venues. *Journal of Interpersonal Violence* 2018 submitted: 10.1177/0886260516657910.
34. **de Andrade D**, Ritchie J, Rowlands M, Mann E, Hides L. Substance use and recidivism outcomes for prison-based drug and alcohol interventions. *Epidemiologic Reviews* 2018; 40: 121-33.
35. **de Andrade DF**, Spittal M, Snow K, Taxman F, Crilly J, Kinner S. Emergency health service contact and reincarceration after release from prison: a prospective cohort study. *Criminal Behaviour and Mental Health* 2018 accepted: 10.1002/cbm.2106.
36. Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrera A, Whiteford H, Leung J, Naghavi M, Griswold M, Rehm J, **Hall WD**, Sartorius B, Scott J, Vollset S, Knudsen A, Haro J, Patton G, Kopec J, Malta D, Topor-Madry R, McGrath J, Haagsma J, Allebeck P, Phillips M, Salomon J, Hay S, Foreman K, Lim S, Mokdad A, Smith M, Gakidou E, Murray C, Vos T. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Psychiatry* 2018; 5: 987-1012.
37. **Demant D**, Hides L, White K, **Kavanagh DJ**. Effects of participation in and connectedness to the LGBT community on substance use involvement of sexual minority young people. *Addictive Behaviors* 2018; 81: 167-74.
38. **Demant D**, Hides L, White KM, **Kavanagh DJ**. LGBT communities and substance use in Queensland, Australia: perceptions of young people and community stakeholders. *PLoS One* 2018; 13: 27.
39. **Demant D**, Oviedo-Trespalacios O, Carroll J, Ferris J, Maier L, Barratt M, Winstock A. Do people with intersecting identities report more high-risk alcohol use and lifetime substance use? *International Journal of Public Health* 2018; 63: 621-30.
40. **Dietrich T**, Mulcahy R, Knox K. Gaming attribute preferences in social marketing programmes: meaning matters more than rewards. *Journal of Social Marketing* 2018; 8: 280-96.
41. Dingwall K, Nagel T, Hughes J, **Kavanagh DJ**, Cass A, Howard K, Sweet M, Brown S, Sajiv C, Majoni S. Wellbeing intervention for chronic kidney disease (WICKD): a randomised controlled trial study protocol. *BMC Psychology* 2018 accepted: 10.1186/s40359-018-0264-x.
42. Durl J, **Dietrich T**, Pang B, Potter L, Carter L. Utilising virtual reality in alcohol studies: a systematic review. *Health Education Journal* 2018; 77: 212-25.
43. Foulstone AR, Kifle T, **Kelly AB**. The influence of partner smoking, relationship satisfaction and parental stress on tobacco use. *Journal of Smoking Cessation* 2018; December 12: 10.1017/jsc.2018.37.
44. Gisev N, Nielsen S, Campbell G, Santo T, Mant A, Bruno R, Cohen M, **Hall WD**, Larance B, Lintzeris N, Farrell M, Degenhardt L. Antidepressant use among people prescribed opioids for chronic noncancer pain. *Pain Medicine* 2018 submitted: 10.1093/pm/pnz009.
45. **Gullo MJ**, Irvine K, Feeney GFX, **Connor JP**. Short message service (SMS) reminders improve treatment attendance in alcohol dependence, but are less effective for patients high in impulsivity. *Addictive Behaviors* 2018; 87: 97-100.
46. **Hall WD**. Minimizing the adverse public health effects of cannabis legalization. *Canadian Medical Association Journal* 2018; 190: e1031-e2.
47. **Hall WD**. The future of the international drug control system and national drug prohibitions. *Addiction* 2018; 113: 1210-23.

48. **Hall WD.** Imperfect international treaties interpreted flexibly are likely to be better than no treaties. *Addiction* 2018; 113: 1230.
49. **Hall WD.** How should we respond to cannabis-impaired driving? *Drug and Alcohol Review* 2018; 37: 3-5.
50. **Hall WD.** Regulating e-cigarettes in Australia: implications for tobacco use by young people. *Medical Journal of Australia* 2018: 10.5694/mja18.00046.
51. **Hall WD.** Finding acceptable ways to fund research on e-cigarettes. *Addiction* 2018 submitted: 10.1111/add.14465.
52. **Hall WD,** Caulkins J, **Stjepanović D,** Campbell G, Leung J, Hickman M, Lynskey M, Vickerman P, Degenhardt L. Global patterns of use, health-related harms, and policies on medical and recreational cannabinoid use. *Lancet* (in preparation).
53. **Hall WD,** Farrell M. The challenges in providing safe, effective, affordable cannabis-based medicines for unapproved indications. *Medical Journal of Australia* 2018; 209: 209-10.
54. **Hall WD,** Farrell M. Reducing the opioid overdose death toll in North America. *PLoS Medicine* 2018; 15: 3.
55. **Hall WD,** Farrell M. Prisoners and risk of injury after release. *Lancet Public Health* 2018; 3: e209-e10.
56. **Hall WD,** Hoch E, Lorenzetti V. Cannabis use and mental health: risks and benefits. *European Archives of Psychiatry and Clinical Neuroscience* 2018 submitted: 10.1007/s00406-019-986-2.
57. **Hall WD,** Kozlowski L. The diverging trajectories of cannabis and tobacco policies in the United States: reasons and possible implications. *Addiction* 2018; 113: 595-601.
58. **Hall WD,** Kozlowski L. Formulating more consistent public health policies towards cannabis and tobacco. *Addiction* 2018; 113: 608-9.
59. **Hall WD,** Morphett K, Gartner C. A critical analysis of Australia's ban on the sale of electronic nicotine delivery systems. *Neuroethics* 2018 submitted: 10.1007/s12152-019-09402-x.
60. **Hall WD,** Parker M. The need to exercise caution in accepting addiction as a reason for performing euthanasia. *Addiction* 2018; 113: 1178-80.
61. **Hall WD,** Parker M. Reasons for ambivalence about accepting addiction as a reason for performing euthanasia. *Addiction* 2018; 113: 1186-7.
62. **Hall WD,** West R, Marsden J, Humphreys K, Neale J, Petry N. The need for more consistent evidential standards in cannabis policy evaluations. *Addiction* 2018; 113: 1553-4.
63. **Hall WD,** West R, Marsden J, Humphreys K, Neale J, Petry N. It is premature to expand access to medicinal cannabis in hopes of solving the US opioid crisis. *Addiction* 2018; 113: 987-8.
64. Hides L, **Chan GCK,** Dawe S, McKetin R, **Kavanagh DJ,** Young R, Teesson M, Saunders JB. Bidirectional relationship between methamphetamine use and positive psychotic symptoms in regular methamphetamine users: evidence from a prospective cohort study. *Lancet Psychiatry* 2018 submitted preprint; THELAN-CETPSYCH-D-18-00818: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3260803.
65. Hides L, Dingle G, Quinn C, Stoyanov SR, Zelenko O, Tjondronegoro D, Johnson D, Cockshaw W, **Kavanagh DJ.** Efficacy and outcomes of a music-based emotion regulation mobile app in distressed young people: randomized controlled trial. *JMIR Mhealth and Uhealth* 2018 submitted: 10.2196/11482.
66. Hides L, Quinn C, Cockshaw W, Stoyanov S, Zelenko O, Johnson D, Tjondronegoro D, Quek LH, **Kavanagh DJ.** Efficacy and outcomes of a mobile app targeting alcohol use in young people. *Addictive Behaviors* 2018; 77: 89-95.

67. Hurley E, Trischler J, **Dietrich T**. Exploring the application of co-design to transformative service research. *Journal of Services Marketing* 2018; 32: 715-27.
68. Ji JLL, **Kavanagh DJ**, Holmes E, MacLeod C, Di Simplicio M. Mental imagery in psychiatry: conceptual & clinical implications. *CNS Spectrums* 2018 accepted: 10.1017/s1092852918001487.
69. **Kavanagh DJ**, Robinson N, Connolly J, **Connor JP**, Andrade J, May J. The revised four-factor motivational thought frequency and state motivation scales for alcohol control. *Addictive Behaviors* 2018; 87: 69-73.
70. Keech JJ, Hatzis D, **Kavanagh DJ**, White KM, Hamilton K. Parents' role constructions for facilitating physical activity-related behaviours in their young children. *Australian Journal of Psychology* 2018; 70: 246-57.
71. Kitunen A, Rundle-Thiele S, Kubacki K, **Dietrich T**. Generating consumer insights into physical activity patterns for three different segments. *Journal of Strategic Marketing* 2018; 26: 188-202.
72. Knox K, **Dietrich T**, Rundle-Thiele S, **Connor JP**. Parent and peer behavior: fueling adolescent binge drinking intentions? *Journal of Consumer Marketing* 2018 submitted: 10.1108/jcm-02-2018-583.
73. Lai FY, Gartner C, **Hall WD**, Carter S, O'Brien J, Tscharke BJ, Been F, Gerber C, White J, Thai P, Bruno R, Prichard J, Kirkbride KP, Mueller JF. Measuring spatial and temporal trends of nicotine and alcohol consumption in Australia using wastewater-based epidemiology. *Addiction* 2018; 113: 1127-36.
74. Lane T, **Hall WD**. Traffic fatalities within US states that have legalized recreational cannabis sales and their neighbours. *Addiction* 2018 accepted: 10.1111/add.14536.
75. Larance B, Campbell G, Moore T, Nielsen S, Bruno R, Lintzeris N, Cohen M, **Hall WD**, Mattick R, O'Donnell C, Degenhardt L. Concerns and help-seeking among patients using opioids for management of chronic noncancer pain. *Pain Medicine* 2018; May 11: 10.1093/pm/pny078.
76. Larney S, **Hall WD**. A major expansion of opioid agonist treatment is needed to reduce overdose deaths in the USA. *Lancet Public Health* 2018 accepted: 10.1016/s2468-667(19)30001-5.
77. Leung J, **Chiu CYV**, **Stjepanović D**, **Hall WD**. Has the legalisation of medical and recreational cannabis use in the USA affected the prevalence of cannabis use and cannabis use disorders? *Current Addiction Reports* 2018; 5: 403.
78. Lucke J, Jensen C, Dunn M, **Chan GCK**, Forlini C, Kaye S, Partridge B, Farrell M, Racine E, **Hall WD**. Non-medical prescription stimulant use to improve academic performance among Australian university students: prevalence and correlates of use. *BMC Public Health* 2018; 18: 7.
79. Maravilla J, Betts K, **Alati R**. Trends in repeated pregnancy among adolescents in the Philippines from 1993 to 2013. *Reproductive Health* 2018; 15: 11.
80. McKetin R, **Hides L**, **Kavanagh DJ**, Saunders JB, Dawe S. First psychotic episode risk markers for primary psychosis amongst people who use methamphetamine. *Schizophrenia Research* 2018; 199: 456-7.
81. Mehus C, Doty J, **Chan GCK**, Kelly AB, Hemphill S, Toumbourou J, McMorris B. Testing the social interaction learning model's applicability to adolescent substance misuse in an Australian context. *Substance Use and Misuse* 2018; 53: 1859-68.
82. Mehus C, Forster M, **Chan GCK**, Hemphill S, Toumbourou J, McMorris B. Longitudinal, reciprocal relationships between family management and antisocial peer associations. *Journal of Adolescence* 2018; 68: 146-51.
83. Morphett K, Carter A, **Hall WD**, Lucke J, Partridge B, Gartner C. Do neurobiological understandings of smoking influence quitting self-efficacy or treatment intentions? *Nicotine & Tobacco Research* 2018; 20: 827-35.

84. Morphett K, **Weier M**, Borland R, Yong HH, Gartner C. Barriers and facilitators to switching from smoking to vaping: advice from vapers. *Drug and Alcohol Review* 2018 submitted: 10.1111/dar.12907.
85. Mucke M, **Weier M**, Carter C, Copeland J, Degenhardt L, Cuhls H, Radbruch L, Hauser W, Conrad R. Systematic review and meta-analysis of cannabinoids in palliative medicine. *Journal of Cachexia Sarcopenia and Muscle* 2018; 9: 220-34.
86. Nielsen S, Germanos R, **Weier M**, Pollard J, Degenhardt L, **Hall WD**, Buckley N, Farrell M. The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews. *Current Neurology and Neuroscience Reports* 2018; 18: 12.
87. Nielsen S, Murnion B, Campbell G, Young H, **Hall WD**. Cannabinoids for the treatment of spasticity. *Developmental Medicine and Child Neurology* 2018 submitted: 10.1111/dmcn.14165.
88. O'Brien JW, Grant S, Banks APW, Bruno R, Carter S, Choi PM, Covaci A, Crosbie ND, Gartner C, **Hall WD**, Jiang G, Kaserzon S, Kirkbride KP, Lai FY, Mackie R, Marshall J, Ort C, Paxman C, Prichard J, Thai P, Thomas KV, Tschärke B, Mueller JF. A National Wastewater Monitoring Program for a better understanding of public health: a case study using the Australian Census. *Environment International* 2018; December 14: 10.1016/j.envint.2018.12.003.
89. **Papinczak ZE**, **Connor JP**, Feeney GFX, Harnett P, Young RM, **Gullo MJ**. Testing the biosocial cognitive model of substance use in cannabis users referred to treatment. *Drug and Alcohol Dependence* 2018; 6 November: 10.1016/j.drugalcdep.2018.09.032.
90. **Papinczak ZE**, **Connor JP**, Harnett P, **Gullo MJ**. A biosocial cognitive model of cannabis use in emerging adulthood. *Addictive Behaviors* 2018; 76: 229-35.
91. Parham SC, **Kavanagh DJ**, Shimada M, May J, Andrade J. Qualitative analysis of feedback on functional imagery training: A novel motivational intervention for type 2 diabetes. *Psychology & Health* 2018; 33: 416-29.
92. Parkinson J, Mkandawire P, **Dietrich T**, Badejo A, Kadir M, Tembo V. Developing the UNICEF Malawi School Handwashing Program. *Social Marketing Quarterly* 2018; 24: 74-88.
93. **Patton KA**, **Connor JP**, Rundle-Thiele S, **Dietrich T**, Young RM, **Gullo MJ**. Measuring adolescent drinking-refusal self-efficacy: development and validation of the Drinking Refusal Self-Efficacy Questionnaire-Shortened Adolescent version (DRSEQ-SRA). *Addictive Behaviors* 2018; 81: 70-7.
94. **Patton KA**, **Connor JP**, Rundle-Thiele S, **Dietrich T**, Young RM, **Gullo MJ**. Validation of the Adolescent Drinking Expectancy Questionnaire and development of a short form. *Drug and Alcohol Review* 2018; 37: 396-405.
95. **Patton KA**, **Connor JP**, Sheffield J, Wood A, **Gullo MJ**. Additive effectiveness of mindfulness meditation to a school-based brief cognitive-behavioral alcohol intervention for adolescents. *Journal of Consulting and Clinical Psychology* 2018 submitted: 10.1037/ccp0000382.
96. **Patton KA**, **Gullo MJ**, **Connor JP**, **Chan GCK**, Kelly AB, Catalano RF, Toumbourou JW. Social cognitive mediators of the relationship between impulsivity traits and adolescent alcohol use: Identifying unique targets for prevention. *Addictive Behaviors* 2018; 84: 79-85.
97. **Patton KA**, Ware R, McPherson L, Emerson E, Lennox N. Parent-related stress of male and female carers of adolescents with intellectual disabilities and carers of children within the general population: a cross-sectional comparison. *Journal of Applied Research in Intellectual Disabilities* 2018; 31: 51-61.
98. Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, Giovino G, West R, **Hall WD**, Griffiths P, Ali R, Gowing L, Marsden J, Ferrari A, Grebely J, Farrell M, Degenhardt L. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. *Addiction* 2018; 113: 1905-26.

99. Plenty S, Evans-Whipp T, **Chan GCK**, Kelly AB, Toumbourou J, Patton G, Hemphill S, Smith R. Predicting alcohol misuse among Australian 19-year-olds from adolescent drinking trajectories. *Substance Use and Misuse* 2018; November 5: 10.1080/10826084.2018.1517172.
100. **Pocuca N**, Hides L, Quinn CA, White MJ, Mewton L, Loxton N. An exploratory study of the relationship between neuroticism and problematic drinking in emerging adulthood, and the moderating effect of social anxiety. *Personality and Individual Differences* 2018 submitted: 10.1016/j.paid.2019.03.022.
101. Pocuca N, Hides L, Quinn CA, White MJ, Mewton L, Newton NC, Slade T, Chapman C, Andrews G, Teesson M, Allsop S, McBride N. The interactive effects of personality profiles and perceived peer drinking on early adolescent drinking. *Psychology of Addictive Behaviors* 2018; 32: 230-6.
102. **Pocuca N**, Hides L, Quinn CA, White MJ, Mewton L, Newton NC, Slade T, Chapman C, Teesson M, Andrews G, Allsop S, McBride N. The interactive effects of perceived peer drinking and personality profiles on adolescent drinking: a prospective cohort study. *Addiction* 2018 accepted 5 October: 10.1111/add.14469.
103. Prichard J, Lai FY, O'Brien J, Bruno R, Thai P, **Hall WD**, Kirkbride P, Thomas K, Mueller JF. "Ice rushes", data shadows and methylamphetamine use in rural towns: wastewater analysis. *Current Issues in Criminal Justice* 2018; 29: 195-208.
104. Puljevic C, Coomber R, **de Andrade D**, Kinner S. Barriers and facilitators of maintained smoking abstinence following release from smoke-free prisons: A qualitative enquiry. *International Journal of Drug Policy* 2018 submitted: 10.1016/j.drugpo.2019.03.018.
105. Puljevic C, Coomber R, Kinner S, **de Andrade D**, Mitchell C, White A, Cresswell S, Bowman J. 'Teabacco': smoking of nicotine-infused tea as an unintended consequence of prison smoking bans. *Drug and Alcohol Review* 2018; 37: 912-21.
106. Puljevic C, **de Andrade D**, Carroll M, Spittal M, Kinner S. Use of prescribed smoking cessation pharmacotherapy following release from prison: a prospective data linkage study. *Tobacco Control* 2018; 27: 474-8.
107. Puljevic C, **de Andrade D**, Coomber R, Kinner S. Relapse to smoking following release from smoke-free correctional facilities in Queensland, Australia. *Drug and Alcohol Dependence* 2018; 187: 127-33.
108. **Quinn CA**, Hides L, de Andrade D, **Pocuca N**, **Wilson M**, **Kavanagh DJ**. Impact of a brief psychoeducational intervention for reducing alcohol use and related harm in school leavers. *Drug and Alcohol Review* 2018 submitted: 10.1111/dar.12920.
109. Rhodes J, May J, Andrade J, **Kavanagh DJ**. Enhancing Grit through functional imagery training in professional soccer. *Sport Psychologist* 2018; 32: 220-5.
110. Robinson NL, Connolly J, Johnson GM, Kim Y, Hides L, **Kavanagh DJ**. Measures of incentives and confidence in using a social robot. *Science Robotics* 2018; 3: 2.
111. Rowland B, Abraham C, Carter R, Abimanyi-Ochom J, **Kelly AB**, Kremer P, Williams J, Smith R, Hall J, Wagner D, Renner H, Hosseini T, Osborn A, Mohebbi M, Toumbourou J. Trial protocol: a clustered, randomised, longitudinal, type 2 translational trial of alcohol consumption and alcohol-related harm among adolescents in Australia. *BMC Public Health* 2018; 18: 7.
112. Rowland B, Williams J, Smith R, Hall JK, Osborn A, Kremer P, **Kelly AB**, Leslie E, Patton G, Mohebbi M, Toumbourou J. Social marketing and community mobilisation to reduce underage alcohol consumption in Australia: a cluster randomised community trial. *Preventive Medicine* 2018; 113: 132-9.
113. Roxburgh A, Pilgrim J, **Hall WD**, Burns L, Degenhardt L. Accurate identification of opioid overdose deaths using coronial data. *Forensic Science International* 2018; 287: 40-6.

114. Shawky S, Kubacki K, **Dietrich T**, Weaven S. Using social media to create engagement: a social marketing review. *Journal of Social Marketing* 2018 accepted: 10.1108/jsocm-05-2018-0046.
115. Silins E, Horwood L, Najman J, Patton G, Toumbourou J, Olsson C, Hutchinson D, Degenhardt L, Fergusson D, Becker D, Boden J, Borschmann R, Plotnikova M, Youssef G, Tait R, Clare P, **Hall WD**, Mattick R. Adverse adult consequences of different alcohol use patterns in adolescence: an integrative analysis of data to age 30 years from four Australasian cohorts. *Addiction* 2018; 113: 1811-25.
116. Solbrig L, Whalley B, **Kavanagh DJ**, May J, Parkin T, Jones R, Andrade J. Functional imagery training versus motivational interviewing for weight loss: a randomised controlled trial of brief individual interventions for overweight and obesity. *International Journal of Obesity* 2018; September 5: 10.1038/s41366-018-0122-1.
117. Stallman H, **Kavanagh DJ**. Development of an internet intervention to promote wellbeing in college students. *Australian Psychologist* 2018; 53: 60-7.
118. Stockings E, Campbell G, **Hall WD**, Nielsen S, Zagic D, Rahman R, Murnion B, Farrell M, Weier M, Degenhardt L. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. *Pain* 2018; 159: 1932-54.
119. Stockings E, Zagic D, Campbell G, Weier M, **Hall WD**, Nielsen S, Herkes G, Farrell M, Degenhardt L. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. *Journal of Neurology Neurosurgery and Psychiatry* 2018; 89: 741-53.
120. Symons M, Feeney GFX, Gallagher M, Young RM, **Connor JP**. Machine learning vs addiction therapists: A pilot study predicting alcohol dependence treatment outcome from patient data in behavior therapy with adjunctive medication. *Journal of Substance Abuse Treatment* 2018 accepted: 10.1016/j.jsat.2019.01.020.
121. Thomas D, Farrell M, McRobbie H, Tutka P, Petrie D, West R, Siahpush M, Gartner C, Walker N, Mendelsohn C, **Hall WD**, Paul C, Zwar N, Ferguson S, Boland V, Richmond R, Doran C, Shakeshaft A, Mattick R, Courtney R. The effectiveness, safety and cost-effectiveness of cytosine versus varenicline for smoking cessation in an Australian population: A study protocol for a randomised controlled non-inferiority trial. *Addiction* 2018; December 27: 10.1111/add.14541.
122. Thomas HJ, **Connor JP**, Scott J. Why do children and adolescents bully their peers? A critical review of key theoretical frameworks. *Social Psychiatry and Psychiatric Epidemiology* 2018; 53: 437-51.
123. Thomas HJ, Scott JG, **Coates JM**, **Connor JP**. Development and validation of the Bullying and Cyberbullying Scale for Adolescents: a multi-dimensional measurement model. *British Journal of Educational Psychology* 2018 submitted: 10.1111/bjep.12223.
124. **Thomas RL**, Kelly AB, **Chan GCK**, **Hides LM**, **Quinn CA**, **Kavanagh DJ**, Williams J. An examination of gender differences in the association of adolescent substance use with eating and weight loss attitudes. *Substance Use and Misuse* 2018; 53: 2125-31.
125. Truong VD, **Dietrich T**. Master's thesis research in social marketing (1971-2015). *Journal of Social Marketing* 2018; 8: 58-98.
126. **Weier M**. Moving beyond vaping as a cessation-only practice. *Addiction* 2018; 113: 406-7.
127. Yucel M, Oldenhof E, Ahmed S, Belin D, Billieux J, Bowden-Jones H, Carter A, Chamberlain S, Clark L, **Connor JP**, Daghli M, Dom G, Dannon P, Duka T, Fernandez-Serrano M, Field M, Franken I, Goldstein R, Gonzalez R, Goudriaan A, Grant J, **Gullo MJ**, Hester R, Hodgins D, Le Foll B, Lee R, Lingford-Hughes A, Lorenzetti V, Moeller S, Munafò M, Odlaug B, Potenza M, Segrave R, Sjoerds Z, Solowij N, van den Brink W, van Holst R, Voon V, Wiers R, Fontenelle L, Verdejo-Garcia A. A transdiagnostic dimensional approach towards

a neuropsychological assessment for addiction: an international Delphi consensus study. *Addiction* 2018; August 22: 10.1111/add.14424.

128. Zahnow R, Miller P, Coomber K, **de Andrade D**, Ferris J. Lessons from Queensland's last-drinks legislation: the use of extended trading permits. *Drug and Alcohol Review* 2018; 37: 537-45.
129. Zimmerman D, Ownsworth T, O'Donovan A, Roberts J, **Gullo MJ**. High-functioning autism spectrum disorder in adulthood: a systematic review of factors related to psychosocial outcomes. *Journal of Intellectual & Developmental Disability* 2018; 43: 2-19.

Books and Book Chapters

130. Barnett A, **Hall WD**, Carter A. Disease, wellness, and addiction: A global perspective. In: Stein D, Singh I, editors. *Global Mental Health and Neuroethics*. Oxford: Oxford University Press; 2018 in press.
131. Carter A, **Hall WD**. From coerced to compulsory treatment of addiction in the patient's best interests Is it supported by the evidence? In: Spivakovsky C, Seear K, Carter A, editors. *Critical Perspectives on Coercive Interventions: Law, Medicine and Society* (pp15-29). Abingdon: Routledge; 2018.
132. **Coates JM**, Feeney GFX, **Gullo MJ**, **Kavanagh DJ**, Young RM, May J, Andrade J, **Connor JP**. Craving measurement and application of the Alcohol Craving Experience questionnaire. In: Preedy V, editor. *The Neuroscience of Alcohol: Mechanisms and Treatment* (pp603-10). London: Academic Press; 2018 in press.
133. **Connor JP**, **Weier M**, **Hall WD**. Age of onset of alcohol use disorders. In: de Girolamo G, McGorry P, Sartorius N, editors. *The Age of Onset of Mental Disorders: Ethio-pathogenetic and Treatment Implications* (pp169-82). Basel: Springer International Publishing AG; 2018 in press.
134. Dawson A, Chandler J, Gavaghan C, **Hall WD**, Carter A. Neuropsychiatric evidence as a mitigating factor in sentencing offenders with addictive behaviours. In: Vincent N, editor. *Neuropsychiatric Evidence and the Criminal Law*. Oxford: Oxford University Press; 2018 in press.
135. Kelly AB, **Thomas RL**, **Chan GCK**. Nicotine use and weight control in young people: implications for prevention and early intervention. In: Preedy V, editor. *The Neuroscience of Nicotine: Mechanisms and Treatment*. London: Elsevier; 2018 in press.
136. **Kelly AB**, **Weier M**, **Hall WD**. Age of onset of substance use disorders. In: de Girolamo G, McGorry P, Sartorius N, editors. *The Age of Onset of Mental Disorders: Ethio-pathogenetic and Treatment Implications* (pp149-67). Basel: Springer International Publishing AG; 2018 in press.
137. Peacock A, **Hall WD**, Degenhardt L. Epidemiology of substance use internationally. In: Sloboda Z, Petras H, Robertson E, Hingson R, editors. *Prevention of Substance Use* (pp19-36). Cham, Switzerland: Springer; 2018 in press.
138. Steindl S, **Connor JP**. Enhancing treatment engagement through motivational interviewing. In: Hadler A, Sutton S, Osterberg L, editors. *The Wiley Blackwell handbook of treatment engagement: theory, research and clinical practice*. Oxford: John Wiley; 2018 in press.

Conference Abstracts

139. **Anderson LE**, Dingle G, O'Gorman B, **Gullo MJ**. Adolescent sexual health: practitioner perspectives in a university context. Paper presented at the 2018 Youth Health Conference: #OwningFutureChange, Gold Coast, Australia: Australian Association for Adolescent Health and the Australian & New Zealand Mental Health Association, 2018. Presenter: Laura Anderson. Available from: <https://www.armchairmedical.tv/youth-18/videos/adolescent-sexual-health-practitioner-perspectives-in-a-university-context-miss-laura-anderson-phd-candidate-the-university-of-queensland>.

140. **Chan GCK**, Morphet K, Gartner C, Leung J, Yong HH, **Hall WD**, Borland R. Poster presentation: Predicting initiation of vaporized nicotine products, frequency of use and ongoing use among daily smokers in longitudinal data from the International Tobacco Control (ITC) Four Country Survey. Paper presented at the College on Problems of Drug Dependence 80th Annual Scientific Meeting, San Diego, 9-15 June 2018.
141. **Coates JM**, **Gullo MJ**, Young RM, Feeney GFX, Dingle G, **Connor JP**. Targeted CBT for Alcohol Use Disorder: results of a randomised controlled trial. Paper presented at the World Psychiatric Association Thematic Congress: Innovation in Psychiatry: Effective Interventions for Health and Society, Melbourne, February 25-February 28 2018.
142. **Connor JP**, **Coates JM**, **Gullo MJ**, Young R, Feeney G. A randomised trial of personalised Cognitive Behaviour Therapy for alcohol use disorder in a public health clinic. Paper presented at the Australian Psychological Society 2018 APS Congress: Psychology Advancing into a New Age, Sydney, 27-30 September. *Australian Psychologist*, Dec 2018; 53: 25. Available from: <https://onlinelibrary.wiley.com/doi/epdf/10.1111/ap.12372>
143. **Connor JP**, **Weier M**, **Chan GCK**, **Hall WD**. Age of onset of drinking and alcohol use disorders. Symposium: Age of onset of mental disorders: Etiopathogenic and treatment implications. Paper presented at the World Psychiatric Association Thematic Congress: Innovation in Psychiatry: Effective Interventions for Health and Society, Melbourne, February 25-February 28 2018.
144. De Andrade D, Hides L, Quinn CA, Elphinston R, Allan J. The effectiveness of residential treatment services for individuals with substance use disorders: a review of recent evidence. Paper presented at the Australasian Professional Society on Alcohol & other Drugs (APSAD) Scientific Alcohol and Drug Conference, Auckland 4-7 November. *Drug and Alcohol Review*, Nov 2018; 37: S26. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/dar.12862>
145. Devilly GJ, **Hides L**, **Kavanagh D**, Sorbello J, Hughes L. The effects of temperance legislation on drinking behaviours in night-time entertainment districts depends on whether people go out to drink or drink to go out. Symposium Presentation 1. Australasian Professional Society on Alcohol & other Drugs (APSAD) Scientific Alcohol and Drug Conference, Auckland 4-7 November. *Drug and Alcohol Review*, Nov 2018; 37: S8. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/dar.12862>
146. Devilly GJ, **Hides L**, **Kavanagh D**, Sorbello J, Hughes L, Allen C. Symposium: drink and other drugs in the entertainment districts of Queensland: preloading, personality and legislation. Corey Allen, Chair. Australasian Professional Society on Alcohol & other Drugs (APSAD) Scientific Alcohol and Drug Conference, Auckland 4-7 November. *Drug and Alcohol Review*, Nov 2018; 37: S7-S8. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/dar.12862>
147. **Dietrich T**, Rundle-Thiele S, Arli D, Kubacki K, **Gullo MJ**, **Connor JP**. Gamifying alcohol education: interim findings from the *Blurred Minds* program. Paper presented at the Agents of Change Summit 2018: The Science and Technology of Behavior Change, San Diego, USA, 12-13 February 2018.
148. Durl J, Kubacki K, **Dietrich T**. Evaluating the effectiveness of a brief versus a comprehensive alcohol social marketing program. Paper presented at the Broadening Cultural Horizons in Social Marketing: Proceedings from the AASM International Social Marketing Conference, Singapore, 15-17 July 2018. Available from: <http://www.aasm.org.au/wp-content/uploads/2018/11/AASM-2018-ISM-Conference-Proceedings.pdf>.
149. **Gullo MJ**. Invited Plenary Speaker and Panellist. From the laboratory to the classroom and clinic: Translational research into youth impulsivity and alcohol use. Paper presented at the 2018 Western Australian Alcohol and Other Drug Conference: Leading the Way: Embracing New Opportunities in the Alcohol and Other Drug Sector, Perth: Mental Health Commission, Government of Western Australia and WA Network of Alcohol and Other Drug Agencies, March 2018.

150. **Gullo MJ.** Invited Speaker and Panellist. Primary prevention methods - Crystal methamphetamine. Paper presented at the Logan Safe City Symposium, Griffith University, Logan Campus, 17 May 2018.
151. **Gullo MJ,** Irvine K, Feeney GFX, **Connor JP.** Short message service reminders improve treatment attendance in alcohol dependence, but not for impulsive patients. Presenter: Matthew Gullo. Australasian Professional Society on Alcohol & other Drugs (APSAD) Scientific Alcohol and Drug Conference, Auckland 4-7 November. *Drug and Alcohol Review*, Nov 2018; 37: S36. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/dar.12862>
152. **Hall WD.** Why does an early age of onset of drug use matter? [Why does an earlier age of onset of drug use predict poorer psychological outcomes in young adulthood?] Symposium 62: Age onset of mental disorders: Etiopathogenic and treatment implications. Paper presented at the World Psychiatric Association Thematic Congress: Innovation in Psychiatry: Effective Interventions for Health and Society, Melbourne, February 25-February 28 2018.
153. **Hall WD.** Invited address: Medical cannabis policy in Australia 1999-2017. Paper presented at the Centre for Alcohol Policy Research, La Trobe University, Bundoora, Victoria, February 2018.
154. **Hall WD.** Invited lecture: The Australian policy debate about e-cigarettes. Paper presented at the National Addiction Centre, Kings College London, London, April 2018.
155. **Hall WD.** Invited paper: A critical analysis of the Australian ban on the sale of electronic nicotine delivery systems. Paper presented at the Brocher Summer Academy in Population-level Bioethics Ethics and Nicotine: Moral Dimensions of Harm Reduction in Tobacco Control, Brocher Foundation, Hermance, Switzerland, May 2018.
156. **Hall WD.** Invited address: Recent research in medical uses of cannabis. Paper presented at the Australian Advisory Council on Medical Uses of Cannabis, Melbourne, August 2018.
157. **Hall WD.** Invited address: Medical cannabis policy in Australia. Paper presented at the Alcohol and Drug Foundation of Australia, Melbourne, August 2018.
158. **Hall WD.** Invited address: Is cannabis safe and effective for medical use? Paper presented at the Queensland Mental Health Review Tribunal, Brisbane, September 2018.
159. **Hall WD.** Invited address: Addiction Neuroethics at The University of Queensland Centre for Clinical Research 2009-2013. Paper presented at the UQCCR 10th Anniversary Symposium, The University of Queensland Centre for Clinical Research, Brisbane, September 2018.
160. **Hall WD.** Invited address: Did medical cannabis programs in some US states pave the way for the legalisation of recreational cannabis use? Paper presented at the International Association of Therapeutic Drug Monitoring and Clinical Toxicology IATDMCT Congress: Top Science Down Under, Brisbane, September 16-19 2018. Available from: <https://iatdmct2018.org/>.
161. **Hall WD.** Invited lecture: Understanding recent developments in North American cannabis policy. Paper presented at the London School of Economics and Political Science and the United States Centre, London, October 8 2018. Available from: <http://www.lse.ac.uk/united-states/events/2018-events/Understanding-recent-developments-in-North-America/Understanding-recent-developments-in-North-American-cannabis-policy>.
162. **Hall WD.** Invited Briefing on medical cannabis for senior policy makers in the UK at the Institute of Psychiatry: Evidence on the safety and effectiveness of cannabis-based medicines. Paper presented at the National Addiction Centre, Kings College London, London, October 2018.

163. **Hall WD.** Invited lecture: Recent developments in cannabis legalisation in the USA, Canada and Uruguay. Paper presented at the National Addiction Centre, Kings College London, London, October 2018.
164. **Hall WD.** Invited presentation to Lancet Editors: Cannabis use, cannabis-related harm and policies to minimise these harms. Paper presented at the The Lancet, London, October 2018.
165. **Hall WD.** Invited lecture: A critical analysis of the justification for the Australian e-cigarettes sales ban. Paper presented at the Centre for History in Public Health Seminar, London: London School of Hygiene and Tropical Medicine, October 2018. Available from: <https://www.lshtm.ac.uk/newsevents/events/critical-analysis-justification-australian-e-cigarettes-sales-ban>.
166. **Hall WD.** Invited lecture: The brain disease model of addiction: is it supported by the evidence and has it lived up to the claims made for it? Paper presented at the National Addiction Centre, Kings College London, London, October 2018.
167. **Hall WD.** Invited Keynote: Global developments in cannabis policy and their potential relevance to Dutch policy. Paper presented at the Cannabiscongres: an initiative of the Trimbos Institute, Utrecht, Netherlands: Trimbos Instituut: Netherlands Institute of Mental Health and Addiction, October 30 2018. Available from: <https://cannabiscongres.trimbos.nl/programma>.
168. **Hall WD.** Invited address: Medical cannabis policies and their implications for the International drug control system. Paper presented at the International Narcotics Control Board, Vienna, November 2018.
169. **Hall WD.** Invited Keynote Address: The challenges in researching the medical uses of cannabinoids. Paper presented at the Inaugural Annual Scientific Meeting, NHMRC Centre for Cannabinoid Clinical and Research Excellence, University of Newcastle, NSW, November 2018.
170. **Hides L, Elphinston R, Quinn CA.** Workshop: Quikfix - a new risk-targeted brief intervention for young people at risk of substance-related harm. Presenter: Leanne Hides. Australasian Professional Society on Alcohol & other Drugs (APSAD) Scientific Alcohol and Drug Conference, Auckland 4-7 November. *Drug and Alcohol Review*, Nov 2018; 37: S16. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/dar.12862>
171. Hides L, **Kavanagh D**, Cotton S, **Connor JP**, Daghli M, Quinn C, Pocuca N, Young R. Is risk-targeted, coping skills enhanced motivational interviewing (MI) more efficacious than MI alone in young people with alcohol related-injuries accessing emergency department and crisis support care? Oral communications: novel treatments strategies: out with the old. Paper presented at the College on Problems of Drug Dependence 80th Annual Scientific Meeting, San Diego, 9-14 June 2018.
172. Hides L, **Kavanagh D**, Daghli M, **Connor JP**, Cotton S. Does targeted coping skills training enhance the efficacy of motivational interviewing (MI) among young people with alcohol related-injuries accessing emergency department and crisis support care? *European Psychiatry*, Mar 2018; 48: S156-S. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/dar.12862>
173. Hu X, Gallagher M, Loveday W, **Connor JP**. Network analysis on prescribing of controlled drugs. Paper presented at the Australasian Computer Science Week (ACSW) 2018, Brisbane, 30 January - 2 February 2018.
174. Hu X, Gallagher M, Loveday W, **Connor JP**. Understanding the interactions between patients and prescribers from prescription data using network statistics. Paper presented at the Advances in Knowledge Discovery and Data Mining: PAKDD 2018 22nd Pacific-Asia Conference, Melbourne, 2018.
175. Kihlas I, Smout A, Mather M, Newton NC, Mills KL, Barrett EL, Touyz SW, Slade T, Chapman C, Stapinski L, Champion KE, Lawler S, Birrell L, McBride N, Allsop S, **Hides L**, Castellanos-Ryan N, Conrod P, Peach N, Cobham V, Ross J, Perrin S, Bendall S, Back S, Brady K,

- Teesson M. Symposium: substance use among adolescents: causes, comorbidities and innovative approaches. Chair: Leanne Hides. Australasian Professional Society on Alcohol & other Drugs APSAD Scientific Alcohol and Drug Conference, Auckland 4-7 November. *Drug and Alcohol Review*, Nov 2018; 37: S12. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/dar.12862>
176. Pang B, **Dietrich T**, Rundle-Thiele S, Kubacki K, Durl J, **Gullo MJ**, Arli D, **Connor JP**. Can serious games reduce excessive drinking intentions among Australian secondary school students? Paper presented at the Broadening Cultural Horizons in Social Marketing: Proceedings from the AASM International Social Marketing Conference, Singapore, 15-17 July 2018. Available from: <http://www.aasm.org.au/wp-content/uploads/2018/11/AASM-2018-ISM-Conference-Proceedings.pdf>.
177. **Papinczak ZE**, **Connor JP**, Feeney GFX, Harnett P, Young RM, **Gullo MJ**. A biosocial cognitive model of cannabis use and dependence: a test among cannabis users referred to drug diversion. Presenter: Zoe Papinczak. Australasian Professional Society on Alcohol & other Drugs APSAD Scientific Alcohol and Drug Conference, Auckland 4-7 November. *Drug and Alcohol Review*, Nov 2018; 37: S55. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/dar.12862>
178. Pocuca N, Hides L, Quinn C, White M, Mewton L, Newton NC, Slade T, Chapman C, Andrews G, Allsop S, McBride N, Birrell L, Shaw B, Te Pas N, Teesson M. Poster: The interactive effects of perceived peer drinking and personality on adolescent drinking trajectories. Paper presented at the College on Problems of Drug Dependence 80th Annual Scientific Meeting, San Diego, 9-14 June 2018.
179. **Quinn CA**, Hides L, De Andrade D, Elphinston R, **Wilson M**, **Kavanagh D**. Impact of brief psychoeducational interventions for reducing alcohol use and related harm in school leavers. Presenter: Catherine Quinn. Australasian Professional Society on Alcohol & other Drugs APSAD Scientific Alcohol and Drug Conference, Auckland 4-7 November. *Drug and Alcohol Review*, Nov 2018; 37: S61. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/dar.12862>
180. **Ralph A**, Harnett P, **Connor JP**, **Gullo MJ**. Emotional dysregulation and impulsivity in the pathway from childhood adversity to problematic substance and alcohol use: a psychophysiological study. Paper presented at the ISAM Busan 2018: 20th International Society of Addiction Medicine Annual Meeting: from the past to the future, Busan, Republic of Korea, 3-6 November 2018.
181. Russell J, **Kavanagh D**, Strodl E, Connolly J. Narrative- and imagery-based treatment for young people with cystic fibrosis. *International Journal of Behavioral Medicine*, Oct 2018; 25: S27-S. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/dar.12862>
182. Stockings E, Campbell G, **Hall WD**, Nielsen S, Zagic D, Rahman R, Murnion B, Farrell M, Weier M, Degenhardt L. Cannabinoids for the treatment of chronic non-cancer pain: an overview of the evidence. Presenter: Emily Stockings. Australasian Professional Society on Alcohol & other Drugs APSAD Scientific Alcohol and Drug Conference, Auckland 4-7 November. *Drug and Alcohol Review*, Nov 2018; 37: S69. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/dar.12862>
183. Stockings E, Campbell G, **Hall WD**, Nielsen S, Zagic D, Rahman R, Murnion B, Weier M, Farrell M, Degenhardt L. Cannabis and cannabinoids for the treatment of people with chronic non-cancer pain conditions: A systematic review and meta-analysis. Paper presented at the College on Problems of Drug Dependence 80th Annual Scientific Meeting, San Diego, June 9-14, 2018.

Reports

184. **Chan GCK**, Expert Working Group. Background paper II: Technical assessment of the Annual Report Questionnaire (ARQ). Vienna: United Nations Office on Drugs and Crime; 2017. Available from: https://www.unodc.org/documents/data-and-analysis/statistics/Drugs/Background_paper_session_II_ARQ_Technical_assessment.pdf.
185. **Chan GCK**, Expert Working Group. Report of the Expert Working Group on improving drug statistics and strengthening of the Annual Report Questionnaire. Vienna: United Nations Office on Drugs and Crime; 2017. Available from: https://www.unodc.org/documents/data-and-analysis/statistics/Drugs/2018EGM_Presentations/FinalReport.pdf.
186. **Hall WD**. Medical use of cannabis and cannabinoids: questions and answers for policymaking. Prepared by Wayne Hall for the European Monitoring Centre for Drugs and Drug Addiction. Luxembourg: Publications Office of the European Union; 2018. Available from: http://www.emcdda.europa.eu/system/files/publications/10171/20185584_TDO618186ENN_PDF.pdf.
187. **Hall WD**. A summary of reviews of evidence on the efficacy and safety of medical use of cannabis and cannabinoids. Background paper commissioned by the EMCDDA for the report: Medical use of cannabis and cannabinoids: questions and answers for policymaking. Luxembourg: Publications Office of the European Union; 2018. Available from: http://www.emcdda.europa.eu/drugs-library/summary-reviews-evidence-efficacy-and-safety-medical-use-cannabis-and-cannabinoids_en.
188. **Hall WD**. Thematic Chapter: Cannabis and cannabinoids for medical, scientific and “recreational” use: risks and benefits. In: INCB, editor. Report of the International Narcotics Control Board for 2018 (pp1-12). Tuesday March 5 ed. Vienna: United Nations; 2018 in press.

Theses

189. **Coates JM**. Personalised treatment for Alcohol Use Disorder: identification and intervention of target mechanisms. A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2018: University of Queensland; 2018.
190. **Demant D**. Substance use among sexual minority young people: the influence of community attitudes and identities. A thesis by publication submitted in fulfilment of the requirements for the degree of Doctor of Philosophy: Queensland University of Technology; 2018.
191. **Patton KA**. Smells like teen spirits: investigating impulsivity and alcohol-related cognition as modifiable risk factors for adolescent alcohol use intervention. A thesis submitted for the degree of Doctor of Philosophy University of Queensland; 2018.
192. **Pocuca N**. Examination of personality risk profiles and alcohol use in young people: submitted in fulfilment of the requirements for the degree of Doctor of Philosophy: QUT; 2018 submitted, awarded 2019.

Staff Listing

Centre Staff Name	Appointment Type	Description
Professor Jason Connor, Director	Academic	Level E, 0.7; Inaugural Director 2008-2013; returned to Director role in 2017 post NHMRC Fellowship, seconded to HaBS from UQ Faculty of Medicine
Professor David Kavanagh, Deputy Director	Academic	Institute of Health Biomedical Innovation (IHBI), Faculty of Health, School of Psychology and Counselling QUT
Associate Professor Matthew Gullo, Senior Research Fellow (NHMRC TRIP Fellow from 2019-)	Academic	Level C, 1.0, 2019- part support from MRFF TRIP Fellowship)
Dr Gary Chan, UQ Research Fellow	Academic	Level B, 1.0 partly supported by UQ Fellowship
Professor Wayne Hall	Academic	Level E, 0.4 FTE Professor, continuing in 2019-2020 at 0.2 FTE
Dr Timo Dietrich, Postdoctoral Research Fellow	Academic	0.4 FTE fully funded from ARC Linkage grant until October 2018
Dr Daniel Stjepanovi , Postdoctoral Research Fellow	Academic	1.0 Level B, funded though DoH project support
Ms Sarah Yeates, Senior Research Assistant	Professional	HEW 7, 0.7 FTE
Professor Annemaree Carroll	Affiliate	Associate Dean, Research, HASS Faculty, UQ
Dr Dominique De Andrade	Affiliate	LLW Research Fellow, School of Psychology, UQ
Associate Professor Genevieve Dingle	Affiliate	School of Psychology, UQ
Professor Leanne Hides	Affiliate	Lives Lived Well (LLW) Chair, School of Psychology, UQ

Centre Staff Name	Appointment Type	Description
Dr Janni Leung	Affiliate	UQ Development Fellow at LLW Group, School of Psychology, UQ
Dr Carla Meurk	Affiliate	Queensland Forensic Mental Health Service, Queensland Health
Associate Professor Louise McCuaig	Affiliate	School of Human Movement and Nutrition Sciences, UQ
Dr Catherine Quinn	Affiliate	LLW Research Fellow, School of Psychology, UQ
Professor John Saunders	Honorary	Professor and Consultant Physician in Internal Medicine and Addiction Medicine, Sydney
Dr Megan Weier	Honorary	Research Associate, Centre for Social Impact, UNSW
Associate Professor Gerald F. X. Feeney	Adjunct	Alcohol and Drug Assessment Unit, Princess Alexandra Hospital
Ms Carrie Fowlie	Adjunct	Executive Officer, Alcohol Tobacco and Other Drug Association ACT (ATODA)
Mr Cameron Francis	Adjunct	Social Worker and Team Leader, Dovetail, Queensland Health
Mr John Kelly	Adjunct	Alcohol and Drug Service, Metro North Hospital and Health Service
Dr Natalie Loxton	Honorary	Senior Lecturer, School of Applied Psychology, Griffith University
Dr Andrew Wood	Adjunct	Lecturer, Clinical Psychology, University of the Sunshine Coast

Our Students

Research Higher Degrees Completed

Student	Supervisors	Title	Degree
Kiri Patton	Gullo, Connor, Sheffield	Smells like teen spirits: investigating impulsivity and alcohol-related cognition as modifiable risk factors for adolescent alcohol use intervention	PhD
Jason Coates	Connor, Gullo, Dingle	Personalised treatment for Alcohol Use Disorder: identification and intervention of target mechanisms	PhD
Daniel Demant (QUT)	Hides	Substance use among sexual minority young people: the influence of community attitudes and identities	PhD
Nina Pocuca (QUT)	Hides	Examination of personality risk profiles and alcohol use in young people	PhD (awarded 2019)

Research Higher Degrees On-going

Student Name	Supervisors	Topics	Degree	Start
Angela Wanigasooriya	Gullo, Connor	Social cognitive predictors of treatment outcomes for amphetamine use and application of a biosocial cognitive model	PhD	2018
Sarah Bryant	Gullo, Harnett	Investigating social-cognitive predictors of alcohol misuse and related risky behaviours among adolescents	PhD	2018
Vivian Chui Ying Chui	Leung, Chan, Hall, Hides	The impacts of legalisation of medical and recreational cannabis	PhD	2018
Laura Anderson	Gullo, Dingle	Preventing sexually transmitted infections in adolescents: A targeted approach	PhD	2017
Freya Young	Gullo, Connor, Harnett	What are the active ingredients? A targeted approach to improving treatment outcomes for alcohol use disorder	PhD	2017
Zoe Papinczak	Gullo, Connor, Harnett	A biosocial cognitive model of youth cannabis dependence	PhD	2016
Annaketurah Ralph	Gullo, Connor, Harnett	The relationship between childhood trauma, attachment style, impulsivity and substance use disorders in adolescents	PhD	2016
Rebekah Thomas	Kelly, Chan	Exploring socio-emotional markers and the development of emerging eating disorder throughout adolescence	PhD	2016
Tim Piatkowski	Hides	Exploring the relationship between self-concept, social influences, body image, and substance use among young men within a Bruss sub-culture	PhD	2015
Charmaine Jensen	Hall, Chan	Non-medical use of prescription stimulants by Australian university students: attitudes, prevalence, and motivation for use	PhD	2013

Major Partners and Collaborators

Research

CYSAR has extensive collaborations and links with other national and international researchers in the alcohol and other drug field. Some examples include:

In Australia

Commonwealth Department of Health and Ageing (ACT)

Griffith University (Qld)

National Centre for Education and Training on Addiction (NCETA)

National Drug and Alcohol Research Centre (NDARC) (NSW)

National Drug Research Institute, Curtin University

Deakin University (Vic)

Turning Point Alcohol and Drug Centre (Vic)

Centre for Adolescent Health, Murdoch Children's Research Institute (Vic)

Orygen Youth Health Research Centre (Vic)

International

European Monitoring Centre on Drugs and Drug Addiction

Kings College London, National Addiction Centre, Institute of Psychiatry

London School of Hygiene & Tropical Medicine

RAND Corporation Drug Policy Research Centre, Santa Monica, California

United Nations Office on Drugs and Crime

University of California, Los Angeles

University of Otago

University of Plymouth

University of Strathclyde

University of Vienna

University of Washington- Alcohol and Drug Abuse Institute

World Bank

World Health Organization (Expert Committee on Drug Dependence)

Industry and Clinical

CYSAR has a number of well-established industry and clinical partners across the drug and alcohol, mental health, emergency, housing and social support sectors. Representatives of many of these services are represented on the CYSAR Advisory Board and have formal UQ affiliate joint appointments with the Centre

These include:

Alcohol and Drug Assessment Unit, Princess Alexandra Hospital

The Alcohol and Drug Assessment Unit (ADAU) is a multidisciplinary outpatient Liaison Clinical Service at a large Australian metropolitan university teaching hospital. The team of doctors, nurses, social workers and psychologists offers assessment and management of problem substance use and problems related to addiction treatment programs for alcohol, tobacco, cannabis, and stimulants. They follow best practice in alcohol and drug treatment, education, research and addictions medicine. This program accepts self-referrals and no formal referrals are required to access the service.

Brisbane Catholic Education

CYSAR partners with BCE to deliver innovative social marketing programs in schools to combat alcohol-related problems. Key components of ARC Linkage Grant funded programs are now embedded in the curriculum of 183 schools in QLD.

Brisbane Youth Services (BYS)

BYS supports homeless and disadvantaged young people (aged 12-25 years) and their children, to secure and maintain housing. They provide emergency support and a range of services to assist young people to address physical and mental health issues, establish successful relationships and support networks, and access education and long term employment.

ChaplainWatch Inc.

ChaplainWatch is an independent Brisbane-based charity, focused on public safety in public spaces. It provides a unique, non-authoritarian service, which encompasses crisis intervention, conflict resolution, front-line first aid, counselling and guidance, secondary victim support, and welfare assistance. This rapid response service works in partnership with other official services. ChaplainWatch are a key partner in the Quikfix early intervention project.

CHQ Children & Youth Mental Health Services (CYMHS)

CYMHS at Children's Health Queensland specialises in helping infants, children and young people up to the age of 18 years who have complex mental health and drug and alcohol needs. CYMHS are a key partner on the Quikfix early intervention research program.

Dovetail

Dovetail is the auspicing body that provides clinical advice and professional support to workers, services and communities across Queensland who engage with young people affected by alcohol and other drug use.

Drug & Alcohol Brief Intervention Team (DABIT; Queensland Health)

Based at key QLD hospitals, the DABIT service model is based on successful services overseas, and targets people with alcohol and drug problems not currently in treatment. Young people attending emergency departments often have substance use problems. For example, road trauma, assaults and injuries are often associated with high risk drinking and other drug usage.

By providing targeted brief interventions, DABIT can reduce the likelihood of patients progressing from substance use to substance dependence. Professor Hides will implement and evaluate the evidence-based Quikfix early intervention model in these services.

Lives Lived Well (LLW)

LLW is the body that auspices the non-government drug and alcohol treatment sector in Queensland. It has a strong focus on young people, Aboriginal and Torres Strait Islander people, and families.

Mater Health Adolescent Drug & Alcohol Withdrawal Service (ADAWS)

ADAWS supports young people through individualised and group support, brief interventions, relapse prevention planning and alternative drug-free activities. The service also aims to reduce drug-related harm by utilising harm reduction strategies that take into account personal goals and choices. ADAWS are a key implementation site of the Quikfix early intervention program and are involved in a number of other treatment studies.

Queensland Alcohol & Drug Information Service (ADIS; Queensland Health)

ADIS provides people with a range of interventions that influence and support the decision to reduce or cease harmful substance use. Referrals to alcohol and other drugs services can come from the individual experiencing the problem, family and friends, community services, Hospital and Health Services, GPs, Police, Courts and Corrective Services.

Queensland Injury Surveillance Unit (QISU; Queensland Health/Mater Health)

Since 1988, Queensland Injury Surveillance Unit (QISU) continuously collects urban injury data from major Brisbane's hospitals, as well as periodically collecting rural data. It has strong collaborations with CYSAR and Professor Hides in her work on preventable youth alcohol and drug injuries.

Scientific Advisory Board

Professor Christina Lee, Chair (Associate Dean [Research], Faculty of Health & Behavioural Sciences, UQ)

Professor Jason Connor (Director, Centre for Youth Substance Abuse Research, UQ)

Professor David Kavanagh (Deputy Director, Centre for Youth Substance Abuse Research; Institute of Health and Biomedical Innovation, QUT)

Professor Doune Macdonald (Pro-Vice-Chancellor [Teaching & Learning], UQ)

Professor Ross Young (Executive Dean, Faculty of Health, QUT)

Professor Leanne Hides (Lives Lived Well Chair in Alcohol, Drugs, and Mental Health, UQ)

Dr Nicholas Carah (Senior Lecturer, School of Communication and Arts, UQ)

Mr Mitchell Giles (CEO, Lives Lived Well)

Ms Carrie Fowlie (Executive Officer, Alcohol Tobacco and Other Drug Association, ACT)

Mr Cameron Francis (Director, Dovetail, Queensland Health)

Ms Rebecca Lang (Chief Executive Officer, Qld Network of Alcohol & Other Drug Agencies)

Ms Liz Minchin (Executive Editor, The Conversation)

The Centre for Youth Substance Abuse Research

17 Upland Road, St Lucia Qld 4072

Tel: +61 344 32536

cysar@uq.edu.au

www.cysar.health.uq.edu.au

